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Abstract 
Introduction: Inflammatory arthritis is a spectrum of diseases arising from immune dysregulation in the 
body causing pain, stiffness, swelling, and tenderness in the joints. In severe cases, it can lead to 
permanent joint damage and even total joint destruction. Due to incomplete understanding of its 
pathogenesis, management has classically been directed at relieving symptoms in the short term, with 
little to no treatment capable of stemming the long-term progression of joint damage. Recently, tumor 
necrosis factor-α (TNF-α) antagonists (or simply, “anti-TNFs”) have revolutionized inflammatory arthritis 
treatment because of their ability to act on the molecules driving joint inflammation. As a result, most 
inflammatory arthritis patients treated with these agents have significant reductions in disease activity. 
Although randomized controlled trials (RCTs) have been instrumental in demonstrating this effect, 
observational studies on the effectiveness and sustainability of anti-TNFs have been lacking. Such 
studies add value by ascertaining the long-term effects of an intervention in a highly generalizable 
population; in short, they are better at revealing real-life conditions.  
Objectives: The two main objectives of this study were to compare the efficacy of a first course of anti-
TNF therapy in three common forms of inflammatory arthritis [rheumatoid arthritis (RA), psoriatic 
arthritis (PsA), and ankylosing spondylitis (AS)], and to compare the first-course efficacy of three widely 
used anti-TNFs (infliximab, etanercept, and adalimumab) within each of RA, PsA, and AS. Secondary 
objectives were to compare the efficacy of first and second courses of anti-TNF therapy in inflammatory 
arthritis patients overall, and to compare the efficacy of a second course of anti-TNF therapy by 
indication (RA, PsA, and AS) and by anti-TNF type (infliximab, etanercept, and adalimumab).  
Methods: This study used a retrospective cohort study design. Efficacy was measured in all cases using 
the proven surrogate outcome of drug survival. Crude anti-TNF survival was compared using Kaplan-
Meier curves with log rank testing, and anti-TNF survival adjusted for several potential confounders was 
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compared using Cox regression with hazard ratios (HRs) for treatment termination. First and second 
course anti-TNF survival was compared using a paired samples t-test. 
Results: 332 patients were eligible for the first-course analysis (114 RA patients, 58 PsA patients, and 
160 AS patients). Crude first-course anti-TNF survival was significantly greater in AS patients compared 
to RA (p = 0.028) or PsA (p = 0.045) patients. However, no significant differences were found between 
RA, PsA, and AS in the adjusted Cox regression. Both crude and adjusted first-course drug survival was 
greater in RA patients taking adalimumab vs. etanercept {p = 0.010 and HR = 0.34 [95% confidence 
interval (CI) 0.14-0.80]}. Male AS patients had superior first-course anti-TNF survival than did female AS 
patients [HR = 0.51 (95% CI 0.27-0.95)]. 98 patients were eligible for the second-course analysis. There 
was no significant difference in drug survival between first and second courses of anti-TNF therapy (p = 
0.443). Both crude and adjusted second-course drug survival was greater in PsA patients than in RA 
patients [p = 0.029 and HR = 0.42 (95% CI 0.19-0.93)]. 
Conclusions: This study helps to validate two key findings observed in previous studies. These are the 
superior first-course anti-TNF survival in AS vs. PsA and RA patients and the superior first-course anti-
TNF survival in male vs. female AS patients. However, it produced few significant findings which is most 
likely attributable to inadequate sample sizes. The greatest value of this study is in the novel questions it 
asked, such that the trends and findings identified here might be useful for generating hypotheses for 
future, sufficiently powered studies. 
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Chapter 1 Introduction 
1.1 Inflammatory Rheumatic Disease 
 Joint pain, or arthralgia, is a very common complaint in the practice of medicine. For the most 
part, arthralgia is caused by degenerative processes such as physical trauma or osteoarthritis. However, 
a small percentage of joint pain is inflammatory in nature and this is known as inflammatory arthritis. 
This inflammation, usually resulting from immune dysregulation in the body, can cause pain, stiffness, 
swelling, and tenderness in the joints. It can also lead to permanent joint damage, potentially rendering 
a joint completely unusable in severe cases. Unfortunately, due to incomplete understanding of its 
pathogenesis, the treatment of inflammatory arthritis has long been a challenge for clinicians. 
Management has classically relied on treating the symptoms of the inflammation, as well as non-
specifically regulating the immune system. This approach, while perhaps capable of controlling pain and 
stiffness in the short term, is ultimately problematic because it only partially modifies disease 
progression and allows for joint damage to insidiously occur. 
 A fairly recent breakthrough in the field of arthritis research has been the development of drugs 
which can act on the very molecules driving joint inflammation. These drugs, known as biologic agents 
(or simply, "biologics”), have revolutionized inflammatory arthritis treatment because they are actually 
capable of significantly modifying disease progression and preventing joint damage in patients. This has 
led to many patients experiencing little to no symptoms of their disease while taking a biologic agent, a 
finding which is very well documented in the abundance of randomized controlled trials (RCTs) on the 
subject.  
However, despite this documented efficacy, the findings of RCTs have not been generalizable 
due to their stringent exclusion criteria, short duration of operation, and unrealistically rigorous follow-
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up procedures. Observational studies address each of these issues, allowing for a different perspective 
on the real-life effect of a biologic agent on disease outcomes. Moreover, in the RCTs performed on this 
subject so far, there is significant variability in response depending on the disease treated and biologic 
agent used; a study which compares arthritis patients’ response to biologic agents both by disease and 
biologic type is absent in the literature. Thus, in this study, we will examine and compare the real-life 
efficacy of the three most widely used biologic agents (infliximab, etanercept, and adalimumab) in 
treating the three most common systemic forms of inflammatory arthritis [rheumatoid arthritis (RA), 
psoriatic arthritis (PsA), and ankylosing spondylitis (AS)] using an observational study design. These 
diseases and drugs will be discussed in detail below. 
1.1.1 Rheumatoid Arthritis 
a) Classification 
 Rheumatoid arthritis is a chronic, systemic, inflammatory disorder which primarily involves the 
synovial joints (Venables, et al., 2010). In 1987, a set of classification criteria was developed by the 
American College of Rheumatology (ACR) which helps determine whether a patient has RA based on 
clinical features, radiographic imaging, and laboratory measures (Quilon, et al., 2010). It states that RA 
can be diagnosed if a patient meets four of the following criteria for at least 6 weeks: 1) morning 
stiffness of the joints, 2) arthritis of 3 or more joint areas, 3) arthritis of the hand joints, 4) symmetrical 
arthritis, 5) rheumatoid nodules, 6) elevated serum rheumatoid factor (RF), and 7) significant 
radiographic changes (e.g. periarticular erosion). Recently, an updated set of criteria has been released 
through collaboration of the ACR and the European League Against Rheumatism (EULAR; Table 1.1) 
(Aletaha, et al., 2010). The primary intent behind the new criteria is to help make an earlier diagnosis. 
For example, instead of including the radiographic damage criterion as in the previous set, the 2010 
criteria include one for detection of the serological marker anti-citrullinated protein antibody (ACPA), 
3 
 
which can appear in RA patients before joint destruction even occurs (Aggarwal, et al., 2009). Other key 
features include a greater emphasis on small joint involvement and a criterion for the detection of C-
reactive protein (CRP), an acute-phase reactant. 
 
 
Table 1.1: The 2010 ACR/EULAR classification criteria for rheumatoid arthritis 
 Score 
Target Population (who should be tested?): Patients who 
1) Have at least 1 joint with definite clinical synovitis (swelling) 
2) With the synovitis not better explained by another disease 
 
Classification criteria for RA (score-based algorithm: add score of categories A-D; a score 
of ≥6/10 is needed for classification of a patient as having definite RA) 
 
A. Joint involvement 
1 large joint 
2 – 10 large joints 
1 – 3 small joints  (with or without involvement of large joints) 
4 – 10 small joints (with or without involvement of large joints) 
>10 joints (at least 1 small joint) 
 
0 
1 
2 
3 
5 
B. Serology (at least 1 test result is needed for classification) 
Negative RF and negative ACPA 
Low-positive RF or low-positive ACPA 
High-positive RF or high-positive ACPA 
 
0 
2 
3 
C. Acute-phase reactants (at least 1 test result is needed for classification) 
Normal CRP and normal ESR 
Abnormal CRP or abnormal ESR 
 
0 
1 
D. Duration of symptoms 
<6 weeks 
≥6 weeks 
 
0 
1 
*ACPA, anti-citrullinated protein antibody; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate 
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b) Epidemiology 
 RA has a worldwide prevalence of approximately 0.5 to 1%, with onset most frequently 
occurring between the ages of 20 and 60. Incidence and prevalence are both two to three times greater 
in women than in men (Uhlig, et al., 2005). 
c) Etiopathogenesis 
 It is still not very clear what specifically causes RA but there is substantial evidence indicating it 
is a multifactorial disease involving genetic, immunological, and environmental determinants. 
 In terms of a genetic component, a recent study of 47,361 RA patients noted a standardized 
incidence ratio of 3.02 in offspring of affected parents, 4.64 in siblings, and 6.48 in twins (Hemminki, et 
al., 2009). Recent single nucleotide polymorphism (SNP)-based genetic studies have helped determine 
some of the specific genetic susceptibility loci which are responsible for this heritability. Although 46 
regions of the genome have been definitively associated with RA, the strongest association has been 
found within the major histocompatibility complex (MHC) and its human leukocyte antigen (HLA) region, 
which is consistent with this region’s major role in the regulation of immunity (Barton, 2010; Eyre, et al., 
2012). HLA-DRB1 is the gene found to have an especially strong association with RA, and although 
several different alleles exist among RA patients of various ethnicities, most of these alleles produce a 
“shared epitope” in the gene product (Barton, 2010). This epitope (a 5-amino-acid sequence) causes a 
significant increase in the relative risk of RA among those who carry it. For example, among Caucasians, 
presence of the HLA-DRB1*0401 allele produces a relative risk of 5 to 11 (Barton, 2010). The HLA-
DRB1*0405 allele, which also contains the shared epitope, has been found increasingly in Chinese and 
Japanese RA patients (Barton, 2010). In some populations, such as African-Americans and Greeks, the 
shared epitope is not present in the majority of RA patients’ DRB1 genes (Barton, 2010). However, its 
5 
 
presence was still significantly higher in both groups’ RA patients compared to their controls, indicating 
the epitope may still play a causative role here as well.  
 The pathogenesis of RA also involves alteration in the immunological pathways. The first of 
these changes is likely the pathologic activation of synovial T cells by one or more unknown antigens 
(Schur, 2010). An inflammatory response ensues, which involves the recruitment and activation of 
additional proinflammatory cells. This leads to pathologic changes in the synovium such as the 
generation of new blood vessels and the migration of leukocytes into the synovial tissue. This synovial 
proliferation is then sustained by a cascade of cytokine1 activity among the synovial lining cells, 
lymphocytes, and various other leukocytes. Several cytokines are involved but tumor necrosis factor-α 
(TNF- α) is thought to be among the most important of these cytokines (Schur, 2010). It promotes 
synovitis by enhancing proliferation of T cells and B cells, enhancing synovial diapedesis of leukocytes, 
increasing expression of proteases involved in joint destruction, and indirectly inducing expression of 
HLA-DR molecules. Synovitis eventually leads to cartilage and bone destruction in the affected joints. 
 Environmental factors have been linked to RA as well. For example, both bacterial and viral 
infections have been studied intensely as possible etiologic factors. Epstein Barr virus (EBV) has been 
linked to RA in several studies. A 1981 study found that the antibody to an EBV nuclear antigen (termed 
RA-associated nuclear antigen) was present in 71% of RA patients versus only 6% of controls (Ferrell, et 
al., 1981). Furthermore, a 2003 study showed that EBV DNA load is increased almost 10-fold in the 
peripheral blood mononuclear cells of RA patients compared to that in controls (Balandraud, et al., 
2003). Bacterial infection has not been linked to RA quite as well as viral infection. However, a 
hypothesis regarding Porphyromonas gingivalis is being investigated which states the bacterium may be 
able to induce RA in genetically susceptible individuals by stimulating citrullinated peptide antibody 
                                                            
1 Cytokines are small proteins involved in intercellular signaling 
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production, a classic diagnostic marker for RA (Wegner, et al., 2010). Another prominently studied 
environmental etiologic factor is smoking. One study found that women who were pack-a-day smokers 
for 20 or more years were 39% more likely to develop RA than women who had never smoked (Karlson, 
et al., 1999). Another study finds that smoking and being homozygous for the HLA-DR shared epitope 
increases the risk of developing RA dramatically (21-fold) relative to that of non-smokers who do not 
carry the shared epitope (Klareskog, et al., 2006). This suggests that environmental and genetic causes 
of RA may act synergistically.  
d) Clinical Features 
The onset of RA is typically gradual and insidious, with the small joints of the hands, wrists, and 
feet being the most commonly affected. As the disease progresses inwardly and symmetrically from the 
periphery, larger joints such as the elbows, shoulders, and knees can also become affected. Symptoms 
include pain, stiffness, and swelling in many of the affected joints. Stiffness is usually particularly severe 
after waking and can last for several hours before returning to normal. RA also leads to cumulative 
structural damage of the joints, which is closely linked to the level of inflammation that causes the 
aforementioned symptoms.  
 RA can also have nonarticular manifestations which are particularly common among patients 
with more severe joint disease. For example, RA patients commonly experience symptoms related to 
lymphocytic infiltration (such as Sjögren’s syndrome2, hypothyroidism, interstitial lung disease, 
splenomegaly, and lymphoma) or vasculitis (such as rheumatoid nodules, scleritis3, mononeuritis 
                                                            
2 Sjögren’s syndrome is an autoimmune disease involving destruction of the salivary and lacrimal glands, resulting 
in dryness of the eyes and mouth 
3 Scleritis is an inflammatory disease of the sclera, the outer coating of the eye 
7 
 
multiplex4, and palpable purpura5) (Schur, et al., 2014). They are also at an increased risk of developing 
metabolic syndrome, with an especially increased incidence of cardiovascular disease. 
e) Management 
It is generally accepted that RA, as well as the other inflammatory arthritides, are managed most 
effectively if a few important principles are followed (Schur, et al., 2009). First is the importance of 
treating the disease as early as possible because untreated disease activity often leads to progressive, 
irreversible joint damage. Also, once initiated, a treatment protocol should achieve tight control of 
disease activity to keep symptoms and damage at bay. Thirdly, all three diseases benefit from general 
health promotion, especially physical exercise which can reduce pain, stiffness, and inflammation. 
Physical therapy, occupational therapy, adequate rest, and patient education all have significant 
therapeutic value as well (Schur, et al., 2010). The most important aspect of management, however, 
may be the use of pharmacologic therapy, which is of critical importance in slowing disease progression 
and achieving tight control of disease activity. 
Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, naproxen, and celecoxib are 
used for treating joint pain in RA patients (Schur, et al., 2009). Patients are also treated with a disease-
modifying anti-rheumatic drug (DMARD) because these drugs help slow down disease progression. 
Methotrexate (MTX) is widely cited as the first line DMARD for treatment of RA. Others often used 
include hydroxychloroquine, sulfasalazine, azathioprine, and leflunomide. These drugs can also be used 
in combination for superior results. One such example is the “triple therapy” of MTX, 
hydroxychloroquine and sulfasalazine (Schur, et al., 2013). Prednisone, a corticosteroid, is also used to 
treat RA symptoms but is avoided whenever possible because of the serious side effects it can cause 
                                                            
4 Mononeuritis multiplex is a disease in which there is damage to two or more nerves in separate parts of the body 
5 Palpable purpura are raised, non-blanching, subcutaneous hemorrhages 
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(e.g. osteoporosis, Cushing’s syndrome, type II diabetes mellitus). If treatment with NSAIDs and multiple 
DMARDs does not adequately control the patient’s disease, the next step is usually to treat with the 
newer biologic drugs (see Section 1.2). In RA, these drugs are often used in combination with MTX 
(Schur, et al., 2010). 
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1.1.2 Psoriatic Arthritis 
a) Classification 
 Psoriatic arthritis is an inflammatory arthritis associated with psoriasis. A subtype of 
spondyloarthritis (SpA), PsA is recognized as a distinct form of arthritis and not the equivalent of, for 
example, RA with coincidental psoriasis (Gladman, et al., 2005). Traditionally, classification of PsA has 
been done using the 1973 criteria developed by Moll and Wright (Moll, et al., 1973). These state that a 
PsA patient must have an inflammatory arthritis, psoriasis, and a negative serology for RF. Meeting 
these three criteria, the PsA patient could then be assigned to one of five subgroups: 1) distal 
interphalangeal (DIP) involvement only, 2) asymmetric oligoarthritis, 3) symmetric polyarthritis, 4) 
spondylitis, or 5) arthritis mutilans6. These classification criteria have a high degree of sensitivity but 
their specificity has been criticized. For instance, one study concludes that some of the patients 
diagnosed using these criteria may have actually had seronegative RA with coincidental psoriasis 
(Helliwell, et al., 2005). Thus, a revised set of criteria favoring specificity has since been developed, the 
2006 Classification criteria for Psoriatic Arthritis (CASPAR; Table 1.2) (Taylor, et al., 2006). CASPAR 
increases specificity by accounting for features such as dactylitis, nail dystrophy, and enthesitis.  
 
 
 
 
 
                                                            
6 Arthritis mutilans is a severe form of arthritis in which the affected joints are destroyed and deformed 
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Table 1.2: The 2006 CASPAR classification criteria for psoriatic arthritis 
A patient is said to have PsA if inflammatory articular disease (joint, spine, or entheseal) is present, 
plus ≥3 total points from any of the 5 categories 
Criterion Points 
1. Evidence of current psoriasis, a personal history of psoriasis, or a family history of 
psoriasis 
- Evidence of current psoriasis on examination 
- Personal history 
- Family history 
 
 
2 
1 
1 
2. Typical psoriatic nail dystrophy (onycholysis, pitting, hyperkeratosis) on examination 1 
3. Negative test for rheumatoid factor 1 
4. Dactylitis (inflammatory swelling of an entire finger or toe) 
- Current dactylitis on examination 
- Personal history 
 
1 
1 
5. Radiographic evidence of juxta-articular new bone formation on plain radiographs of 
hands or feet 
1 
 
 
b) Epidemiology 
 The prevalence of PsA is approximately 0.2% in the general population (Gladman, 2009). Its 
prevalence among psoriasis patients is quite variable (i.e. 6 to 42%) and this is attributable to differences 
in the definition of, and ascertainment strategies for identifying, inflammatory arthritis (Haddad, et al., 
2012). However, the most recent study from general practice databases in the UK reports a 14% 
prevalence of inflammatory arthritis among psoriasis patients as defined by the CASPAR criteria 
(Ibrahim, et al., 2009). PsA affects men and women equally and the peak age of onset is between 30 and 
50 years (Khan, 2002). 
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c) Etiopathogenesis 
 PsA exhibits a strong genetic component, with first-degree relatives of PsA patients being 30 to 
55 times more likely to develop the disease than the general population (as reviewed by Rahman, et al., 
2005). The most strongly associated genetic susceptibility loci have been identified within the HLA 
region. HLA-B27, for example, is commonly found in AS patients but is also found fairly frequently in PsA 
patients, particularly in those with spinal involvement (Gladman, et al., 1986). Other alleles, HLA-B38 
and HLA-B39, are expressed more commonly in PsA patients with peripheral polyarthritis (Rahman, et 
al., 2005). Another MHC gene, HLA-Cw6, is associated with an earlier onset of psoriasis in PsA patients 
(Gladman, et al., 1999).  
As in the proposed pathogenesis of RA, the products of these abnormal HLA genes are thought 
to be involved in pathologic T cell activation. This is supported by the observation of prominent T cell 
infiltration in PsA patients’ skin and joint lesions (Veale, et al., 2002). Hyperplasia, angiogenesis, and the 
elevated production of pro-inflammatory cytokines such as TNF-α, IL-2, and interferon-gamma (IFN-γ) 
are other pathologic features seen in the joints and skin (Veale, et al., 2002). TNF-α in particular is 
thought to be heavily involved in the pathogenesis of PsA due to its role in activating synovial fibroblasts 
and osteoclasts, and in enhancing extravasation of leukocytes into the synovium (Choy, et al., 2001). 
Physical trauma may be etiologically linked to PsA as well. The Koebner phenomenon, named 
for the 19th century dermatologist who discovered it, describes the development of psoriatic lesions on 
areas of skin subjected to mechanical, physical, or chemical trauma. This effect has since been 
substantiated by several case reports and controlled studies (Veale, et al., 2002). Joint inflammation in 
PsA patients may arise from physical trauma as well, with one study noting a higher incidence of PsA 
following trauma than either RA or AS (Punzi, et al., 1998). 
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d) Clinical Features 
The onset of PsA typically begins with the development of psoriatic lesions, which can be found 
on both the skin and nails (Gladman, 2009). Skin lesions manifest mostly as inflamed areas covered with 
scaly white patches of skin called plaques. Nail lesions, which occur in 87% of PsA patients, mostly 
manifest as onycholysis (nail detachment) and as depressions in the nails called pits (Gladman, et al., 
2005). 
Although it can precede the onset of psoriasis in some PsA patients, joint disease in the majority 
of patients develops many years after psoriatic lesions have formed  (Gladman, et al., 2005). Patterns of 
joint involvement among PsA patients can be very different. The most common patterns are symmetric 
polyarthritis and asymmetric oligoarthritis, but spondyloarthritis and DIP arthritis can also occur. These 
latter two subtypes of PsA usually occur with peripheral arthritis. Arthritis mutilans, a condition in which 
joints are deformed and destroyed, can occur in conjunction with any of these patterns. In terms of 
symptoms, PsA patients are similar to those with RA in that they experience pain and stiffness in their 
joints, both of which are particularly severe in the morning. However, tenderness of the joints tends to 
be less severe in PsA in comparison to other inflammatory arthritides (Buskila, et al., 1992). Apart from 
skin and joint involvement, PsA patients can also present with pitting edema in the hands and feet; 
anterior uveitis also occurs in some patients.  
e) Management 
The treatment strategy for PsA is guided heavily by the severity of the disease manifestations 
(Gladman, 2010). In 2009, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 
(GRAPPA) published a set of evidence-based treatment recommendations for PsA (Table 1.3) (Ritchlin, 
et al., 2009). These guidelines give a separate algorithm for each of the 5 most common clinical 
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manifestations of PsA; the most severe manifestation dictates the treatment strategy. For example, if 
peripheral arthritis is the most severe feature of a patient’s PsA, the algorithm states to first try treating 
with NSAIDs, then intra-articular steroids, then DMARDs, and finally biologic agents if all else fails. 
DMARDs used effectively for PsA include MTX, leflunomide, sulfasalazine, and cyclosporine. For PsA 
patients with severe psoriasis, treatment with psoralen and ultraviolet light A (PUVA) can be used in 
conjunction with a DMARD. Notably, following this treatment strategy often helps alleviate the arthritic 
and psoriatic symptoms of PsA patients.  
 
Table 1.3: The GRAPPA treatment guidelines for psoriatic arthritis, categorized by disease 
characteristics and distinct organ involvement 
 Treatment 
PsA manifestation 1st line 2nd line 3rd line 4th line 
Peripheral arthritis NSAID IA steroids DMARD (MTX, 
CsA, SSZ, LEF) 
Biologics (anti-
TNF) 
Skin and nail diseases Topicals PUVA/UVB Systemics (MTX, 
CsA, etc.) 
Biologics (anti-
TNF, etc.) 
Axial disease NSAID PT Biologics (anti-
TNF) 
______ 
Dactylitis NSAID Injection Biologics (anti-
TNF) 
______ 
Enthesitis NSAID PT Biologics (anti-
TNF) 
______ 
* CsA, cyclosporin A; IA, intra-articular; LEF, lefunomide; PT, physiotherapy; UVB, ultraviolet light B 
 
 
14 
 
1.1.3 Ankylosing Spondylitis 
a) Classification 
 Ankylosing spondylitis is a chronic, inflammatory disease which primarily affects the axial joints. 
Until recently, the 1984 modified New York classification criteria had been widely used to diagnose AS 
(Quilon, et al., 2010). They state that an AS patient must have radiological evidence of sacroiliitis (either 
grade 2 to 4 bilaterally or grade 3 to 4 unilaterally) and meet one of the following criteria: 1) 3 or more 
months of low back pain that improves with exercise but not with rest, 2) restriction of lumbar spine 
movement in the sagittal and frontal planes, and 3) chest expansion decreased relative to normal values 
for age and sex.  
These criteria have recently undergone major changes to help make an earlier diagnosis of 
arthritis. The idea here is to recognize the potential for developing AS before radiological evidence of 
sacroiliitis even occurs. This was done by incorporating newer diagnostic techniques (e.g. MRI) and 
including a test for the HLA-B27 allele, which has a very strong association with AS. Such changes reflect 
the evolving definition of spondyloarthritis (SpA), the family of arthritides affecting the vertebral column 
to which AS belongs. These newer criteria are called the Assessment of SpondyloArthritis international 
Society (ASAS) classification criteria for axial spondyloarthritis (Table 1.4) (Sieper, et al., 2009). There are 
also classification criteria for peripheral SpA, another spondyloarthropathy with predominantly 
peripheral features such as dactylitis. 
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Table 1.4: The 2009 ASAS classification criteria for axial spondyloarthritis 
In patients with ≥3 months of back pain and age of onset <45 years 
Sacroiliitis on imaging* 
plus 
≥1 SpA feature# 
 
or 
HLA-B27 
plus 
≥2 other SpA features* 
   
*Sacroiliitis on imaging: 
- Active (acute) inflammation on 
MRI highly suggestive of 
sacroiliitis associated with SpA 
- Definite radiographic sacroiliitis 
according to modified NY criteria 
#SpA features 
- Inflammatory back pain 
- Arthritis 
- Enthesitis (heel) 
- Uveitis 
- Dactylitis 
- Psoriasis 
- Crohn’s/colitis 
- Good response to NSAIDs 
- Family history for SpA 
- HLA-B27 
- Elevated CRP 
 
 
b) Epidemiology 
 AS is the most common form of spondyloarthritis with a prevalence of 1 to 3 out of every 
thousand in white populations (Brown, et al., 2003). It has a peak onset between 20 and 30 years and it 
affects more than twice as many men as women. Men generally develop AS at a younger age than 
women and their arthritis tends to be primarily axial, whereas women are more likely to have peripheral 
arthritis as well (Mori, et al., 2003). Men are also more likely than women to experience extra-articular 
manifestations of AS such as inflammatory bowel disease (Breban, et al., 2003). 
c) Etiopathogenesis 
 AS has a very strong genetic component for a complex genetic disease. The recurrence risk ratio 
for siblings of probands with AS ranges from 50 to 80 and the heritability from twin studies is estimated 
to be over 90% (Brown, et al., 2002). Presently there are 27 genetic regions or genes reaching genome 
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wide significance for AS (Yu, 2011; International Genetics of Ankylosing Spondylitis Consortium, 2013). 
New genetic susceptibility loci have been identified for AS, including genes encoding two interleukin (IL) 
receptors and one encoding an anthrax toxin receptor, but the strongest association is again with a gene 
in the HLA region, HLA-B27 (Yu, 2011). This particular allele of the HLA-B gene is present in about 95% of 
AS patients in the US, China, and Europe, compared to a presence of less than 10% in each of those 
nations’ general populations (Feltkamp, et al., 2001). HLA-B27 has many known subtypes and the most 
common subtype among Caucasians, B*2705, is highly associated with AS. This susceptibility is thought 
to be induced by substitutions in important amino acid residues of the HLA-B27 molecule, causing it to 
present abnormally conformed antigenic peptides to the T cells it normally interacts with (Yu, 2011). 
 The first immunological event leading to the onset of AS is thought to be the pathologic 
activation of CD8+ T cells by the peptide-presenting HLA-B27 protein. The host is normally tolerant of 
self-peptides presented by HLA-B, but autoimmunity can arise if these peptides bind in an alternative 
conformation so as to mimic microbial peptides.  Following this pathologic T cell activation, an 
inflammatory response similar to that in RA occurs where cytokine activity is increased and then 
maintained, which eventually leads to proteolytic destruction of the joints. As in RA, TNF-α is thought to 
be an important factor in the disease process of AS (Yu, 2011). Studies have shown it to be more highly 
expressed in AS patients than in healthy controls (Bal, et al., 2007; Gratacos, et al., 1994).  
 Infection has also been heavily studied as an etiologic factor for AS. Although there is no 
definitive evidence for the role of microbial pathogenesis in human patients, experimentation with 
animal models has shown that bacterial agents may be involved. For example, one study found that 
HLA-B27—transgenic rats do not develop symptoms of AS in a germ-free environment but rats of the 
same litter will develop the disease in a normal environment (Taurog, et al., 1994). Of the several 
bacteria investigated as potential triggers of AS, Klebsiella pneumoniae has received the most attention 
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because of the homology existing between some of its proteins and HLA-B27 (Shamji, et al., 2008). Thus 
antibodies produced against these homologous Klebsiella proteins would be cross-reactive with HLA-
B27. It has been shown that anti-Klebsiella antibodies bind more significantly to the synovial tissues of 
HLA-B27(+) AS patients than to those of healthy controls (Rashid, et al., 2007). Furthermore, 
experimental evidence suggests that anti-Klebsiella antibodies are significantly elevated in AS patients 
relative to healthy controls (Tani, et al., 1997; Sahly, et al., 1998).  
d) Clinical Features 
The effects of AS are felt mostly in the spinal and sacroiliac joints, with a slightly lesser degree of 
involvement in the sternum, ribs, hips and shoulders (Yu, 2010). Inflammation of peripheral, distal joints 
may occur in some cases but it typically manifests as acute, non-deforming monoarthritis. Enthesitis, 
inflammation of the area of ligament or tendon insertion into bone, is a characteristic feature of AS.  
 The first symptom of AS in 75% of patients is low back pain. This inflammatory spinal pain is 
distinct from mechanical back pain in that it actually improves with exercise and worsens with rest. As 
the disease progresses, postural abnormalities, and reduced spinal mobility and chest expansion may 
also become apparent. At its most advanced stage, AS can result in the fusion of the entire spine and 
complete loss of spinal mobility (Mori, et al., 2003). Also, pain and stiffness commonly develop in other 
joints like the sacroiliac joints, hips, knees, and shoulders. 
 AS patients can experience several extra-articular manifestations as well. The most common 
complication is acute anterior uveitis, which causes unilateral eye pain, photophobia, and blurred vision. 
AS can also cause respiratory issues by mechanically restricting the upper airways; patients can 
experience a decrease in chest expansion and therefore lung capacity. Inflammatory bowel disease also 
occurs in AS patients, and the risk for aortic insufficiency is significantly greater in these patients as well. 
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e) Management 
The management of AS ranges from very conservative to intense pharmacologic treatment. For 
instance, occasionally there are cases where no significant intervention is required to control symptoms. 
This usually occurs in patients who are well oriented to their disease, have minimal symptoms, good 
posture, and are physically active. A larger subset of patients benefits from formal physiotherapy. 
Therapy might include postural training, range of motion stretching, recreational activities, and 
hydrotherapy (Yu, 2010a). 
In terms of pharmacologic therapy, NSAIDs may be quite effective in AS patients whereas most 
DMARDs are not effective in treating the axial symptoms of spondylitis (Yu, 2010a). The only DMARD 
that is normally prescribed in the event of NSAID failure is sulfasalazine, which is only useful for treating 
peripheral symptoms (e.g. oligoarthritis of the knees and/or ankles). Intra-articular corticosteroid 
injections can also be used to relieve symptoms but long-term use is not recommended. If the patient’s 
disease remains active despite trying at least two to three different NSAIDs (and at least one DMARD if 
their disease is predominantly peripheral), the patient is considered a candidate for biologic therapy (Yu, 
2011; see Section 1.2). Table 1.5 shows a treatment strategy for AS developed through collaboration of 
ASAS and EULAR (Zochling, et al., 2006). 
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Table 1.5: The ASAS/EULAR recommendations for the management of AS 
Non-pharmacological treatment (education, exercise, PT, rehabilitation, patient associations, self-help groups) plus:  
 Treatment 
AS manifestation 1st line 2nd line 3rd line 4th line 
Axial disease 
 
NSAIDs ______ ______ TNF-α antagonists 
Peripheral disease NSAIDs SSZ Local 
corticosteroids 
TNF-α antagonists 
Refractory disease 
(either) 
Analgesics 
---------- Surgery 
*SSZ, sulfasalazine; PT, physiotherapy 
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1.2 Biologic Therapy 
1.2.1 Inflammatory Rheumatic Disease and Cytokine Activity 
 The traditional treatment strategies for each of the three arthritides, mainly involving NSAIDs 
and DMARDs, work well for many patients but do not adequately control disease activity for many 
others (Schur, et al., 2013; Yu, et al., 2013; Kyle, et al., 2004). Research into more effective and yet 
relatively safe treatment options for inflammatory rheumatic disease is therefore ongoing.  
As was previously discussed, the precise pathogeneses of RA, AS, and PsA have not been clearly 
identified but numerous observations made over decades of research suggest that genetic, 
immunological, and environmental factors are all involved (Cassell, et al., 2005; Perl, 1999). Perhaps one 
of the most important breakthroughs in the last 20 years or so has been in the realm of immunological 
research with the discovery of pro-inflammatory cytokines. Cytokines, small proteins involved in 
intercellular signaling, are thought to play an important role in mediating the inflammatory process of all 
three arthritides (Choy, et al., 2001). While it is possible this process may be initiated much farther 
upstream by some genetic or environmental abnormality, the modification of cytokine activity is proven 
to have a significant effect on joint inflammation and damage (Choy, et al., 2001). Thus, specific 
inhibition of the cytokines responsible would represent the next innovation in drug therapy for 
inflammatory arthritis. 
 Tumor necrosis factor-α (TNF-α) is probably the most important of these cytokines (Choy, et al., 
2001). It stimulates its own production and that of other inflammatory cytokines such as IL-1 and IL-6. It 
also stimulates the production of adhesion molecules by fibroblasts, which ultimately leads to the 
transportation of leukocytes to joint areas. Furthermore, it increases the expression of several proteases 
involved in joint destruction such as the matrix metalloproteinases of osteoclasts (McInnes, 2010). 
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Research into TNF-α inhibition has been intense, resulting in the creation of four medications7 approved 
for use in RA, PsA, and AS: infliximab, etanercept, adalimumab, and golimumab. 
 
1.2.2 Tumor Necrosis Factor-α Antagonists 
 Drugs designed to inhibit TNF-α, known as TNF-α antagonists (or “anti-TNFs”), are an example of 
a relatively new class of drugs called biologic agents. These agents are so named because they are 
synthesized biologically using human, animal, or bacterial cell cultures. This is significant because it 
allows for the production of compounds which are very similar to those naturally occurring in the body’s 
immune system. Biological synthesis is a considerable departure from the chemical synthesis used to 
produce NSAIDs and DMARDs, which are relatively small molecules with virtually no likeness to any 
compounds produced endogenously. The products of biological synthesis, on the other hand, are usually 
large molecules such as proteins or nucleic acids designed with very specific functions. In the case of 
TNF-α inhibition, these molecules are either anti-TNF-α monoclonal antibodies or soluble TNF-α 
receptors. 
a) Infliximab 
 Infliximab is a synthetic, monoclonal antibody that binds specifically to both soluble and 
membrane-bound TNF-α. The antibody is chimeric, incorporating murine variable regions with a human 
constant region. Infliximab works by binding TNF-α and neutralizing its activity by preventing it from 
binding its receptors.  
                                                            
7 A fifth TNF-α antagonist, certolizumab, has recently been approved for use in RA, PsA, and AS but was not in use 
at the time our research was performed 
22 
 
The first randomized, placebo-controlled trial (RCT) testing the efficacy and safety of infliximab 
treatment in inflammatory rheumatic disease was a 1994 study involving 73 RA patients (Elliott, et al., 
1994). Separated into three groups, the patients were given a single intravenous infusion of 1 mg/kg 
infliximab, 10 mg/kg infliximab, or placebo. After 4 weeks, 8% of the placebo group, 44% of the low-dose 
group, and 79% of the high-dose group had a 20% Paulus response8 or better. Also, only 2 of 73 patients 
experienced severe adverse events during the study. Another study done in 1999 demonstrated the 
therapeutic potential of infliximab when combined with MTX. It was found that among RA patients who 
were not previously responding to MTX alone, the addition of infliximab significantly improved their 
symptoms according to ACR criteria (Figure 1.1A) (Maini, et al., 1999). In response to these findings, 
infliximab in combination with MTX therapy was approved by the US Food and Drug Administration 
(FDA) for treatment of RA in 1999. The requirement for concomitant MTX therapy is due to infliximab’s 
chimeric nature, which results in the development of anti-infliximab antibodies and reduced efficacy in 
some patients. Concomitant MTX has been shown to decrease levels of these antibodies in RA patients 
(Maini, et al., 1999). 
 Infliximab was approved for use in AS in 2004 and PsA in 2005 after RCTs had shown that the 
drug was effective against those diseases as well (Figure 1.1B,C) (van der Heijde, et al., 2005; Antoni, et 
al., 2005). Its efficacy as a treatment for each of the three arthritides has since been well documented. 
For instance, in RA, it has been shown to improve physical function and retard joint damage (Chen, et 
al., 2006); in AS, it has been effective at improving both axial and peripheral symptoms (Yu, 2010a); and 
in PsA, it has been shown to improve symptoms of both the skin and joint diseases, as well as inhibit 
radiographic progression (Gladman, 2005).  
 
                                                            
8 The Paulus response is an endpoint which amalgamates improvement in the patient’s joints, global assessment, 
and ESR 
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                                A                                                B                                                       C 
Figure 1.1: Percentages of patients that obtained an ACR20 or ASAS20 response in RCTs evaluating 
infliximab treatment in RA, PsA, and AS. PBO, placebo; IFX, infliximab. 
 
b) Etanercept 
 Etanercept is a synthetic, soluble TNF-α receptor produced by the expression of recombinant 
DNA. It is a fusion protein that combines the human TNF-α receptor with the Fc component of human 
immunoglobulin G1 (IgG1). By acting as a decoy receptor for TNF-α, it essentially has the same effect as 
infliximab: neutralization of TNF-α activity.  
An RCT investigating etanercept’s use in RA patients was first conducted in 1997. 180 patients 
with active RA were randomized to placebo or one of three doses of etanercept twice weekly for three 
months (Moreland, et al., 1997). A dose-related effect was observed such that 75% of patients on the 
highest dose of etanercept obtained a 20% or better improvement in symptoms according to ACR 
criteria (ACR20 response); only 14% of placebo group patients obtained an ACR20 response (Figure 
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1.2A). This led to etanercept becoming the first TNF-α antagonist approved for use in RA by the FDA in 
1998. Subsequent approval for use in PsA in 2002 and AS in 2003 also resulted from the promising 
findings of RCTs (Figure 1.2B,C) (Mease, et al., 2004; Davis, et al., 2003). For instance, treatment with 
etanercept produces at least an ASAS20 response9 in a majority of patients with active AS (Davis, et al., 
2003) and at least an ACR20 response in a majority of PsA patients (Mease, et al., 2000). The skin 
disease of PsA patients is also improved by treatment with etanercept (Mease, et al., 2004). 
 
 
                                A                                                B                                                       C 
Figure 1.2: Percentages of patients that obtained an ACR20 or ASAS20 response in RCTs evaluating 
etanercept treatment in RA, PsA, and AS. ETN, etanercept; BSA, body surface area. 
 
                                                            
9 An ASAS20 response is an endpoint signifying a 20% improvement in AS symptoms defined by the Assessment in 
Ankylosing Spondyltis criteria. The criteria include pain, function, inflammation, and global disease activity scores. 
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c) Adalimumab 
 Like infliximab, adalimumab is a monoclonal antibody that binds all forms of TNF-α and 
neutralizes its activity. However, adalimumab is a humanized monoclonal antibody (i.e. it has human 
constant and variable regions) whereas infliximab is a chimeric monoclonal antibody (i.e. it has human 
constant regions and murine variable regions). This difference is designed to make adalimumab less 
immunogenic for patients who use it.  
The first prominent RCT to test the efficacy of adalimumab in RA patients was conducted in 
1999. 283 patients with active disease were randomized to placebo or one of three weekly doses of the 
drug for 12 weeks (van de Putte, et al., 1999). At study’s end, a dose-dependent improvement was 
observed as 56% of the high-dose group obtained an ACR20 response or better; only 10% of the placebo 
group achieved this outcome. Another study in 2001 assessed the efficacy of adalimumab in 
combination with MTX therapy in RA patients and found that this treatment was significantly better 
than MTX alone (Keystone, et al., 2001). Adalimumab was then approved by the FDA for treatment of 
RA in 2002 (Figure 1.3A) (van de Putte, et al., 2004). Co-therapy with MTX is considered optional since 
adalimumab is fully humanized and thus minimally immunogenic. Similar RCTs provided the empirical 
evidence needed to approve the drug for PsA in 2005 and AS in 2006 (Figure 1.3B,C) (Mease, et al., 
2005; van der Heijde, et al., 2006). Since its approval, the drug has proven efficacious at improving joint 
pathology in RA (van de Putte, et al., 2004), AS (van der Heijde, et al., 2006), and both joint and skin 
pathology in PsA (Mease, et al., 2005) (Figure 1.4). 
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                                A                                                B                                                       C 
Figure 1.3: Percentages of patients that obtained an ACR20 or ASAS20 response in RCTs evaluating 
adalimumab treatment in RA, PsA, and AS. ADA, adalimumab. 
 
 
d) Golimumab 
 Golimumab is a humanized monoclonal antibody which binds to both soluble and 
transmembrane forms of TNF-α and neutralizes its activity.  
The first prominent, multicenter RCT testing the safety and efficacy of golimumab in RA patients 
was conducted very recently, in 2008 (Keystone, et al., 2009). The study randomized 444 patients to four 
experimental groups: placebo plus MTX, golimumab 100 mg plus placebo, golimumab 50 mg plus MTX, 
or golimumab 100 mg plus MTX. Injections of golimumab and its placebo were administered once every 
four weeks. After 24 weeks of therapy, the investigators found the combination of golimumab and MTX 
produced an ACR20 response which was significantly greater than that obtained with either golimumab 
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or MTX alone. Following the results of this and similar studies, golimumab was approved for treatment 
of RA in early 2009. An RCT has also been done to test the efficacy of golimumab monotherapy in each 
of PsA and AS; the positive results generated from both studies has led to approval of golimumab for 
PsA and AS in 2009 as well (Kavanaugh, et al., 2009; Inman, et al., 2008). Although it shows great 
promise as a biologic treatment for inflammatory arthritis, golimumab cannot yet be studied 
longitudinally due to its very recent approval. This limitation means it must be omitted from the present 
study. 
 
1.2.3 Management of Inflammatory Arthritis with TNF-α Antagonists 
 Once a decision has been made to place a patient on anti-TNF therapy, the effectiveness of the 
treatment is monitored by routinely assessing disease activity (both clinically and using laboratory 
values), functional status, radiographic progression, and drug toxicity. The therapeutic target is tight 
control of all of these parameters, resulting in a state of remission or minimal disease activity. If this 
target is achieved with the first anti-TNF agent, treatment is continued indefinitely. If this target is not 
achieved within the first 6 months (i.e. the patient is a primary non-responder), switching to therapy 
with an alternative mechanism of action (i.e. not involving TNF-α inhibition) is indicated. If the patient 
begins to fail anti-TNF therapy after 6 months (i.e. a secondary non-responder), adjustments will be 
made to the type/dosage of DMARDs and/or the type of anti-TNF agent. If a severe adverse event 
secondary to anti-TNF therapy occurs (e.g. lymphoma or reactivated tuberculosis), the anti-TNF agent is 
stopped permanently or held and restarted at a later date at the discretion of the rheumatologist. 
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1.3 Rationale 
 Although they have all been approved for the treatment of RA, PsA, and AS in the last 17 years, 
TNF-α antagonists remain topical in medical research due to their ever-increasing use by arthritis 
patients. Several RCTs have been conducted to exhaustively determine the efficacy and safety of each 
anti-TNF as a treatment for each form of inflammatory arthritis (van de Putte, et al., 2004; Keystone, et 
al., 2004; van der Heijde, et al., 2005). The knowledge gleaned from these studies has been critical to 
guiding the treatment decisions of rheumatologists. However, despite their potential to produce 
internally valid, unbiased results, clinical trials often lack generalizability. Their patient populations are 
often homogeneous and free of significant comorbidities; monitored at an unrealistically high 
frequency; artificially motivated to remain on the study drug which is often free of charge for them; and 
followed for too short a duration to ascertain long-term drug effectiveness. 
 Observational studies can be used to address all of these issues. While its results are more 
vulnerable to bias than those of an RCT, an observational study’s ability to assess the real-life effects of a 
drug on a population is unparalleled by most RCTs. For instance, generalizability can be increased by 
minimizing population exclusion criteria and by selecting the patient population from a typical clinical 
setting, where patients are assessed at a realistic frequency and without study-related incentives to 
remain on the study drug. Also, whereas an RCT incurs additional costs when its follow-up period is 
extended beyond what is initially planned, longitudinal follow-up in an observational study is far less 
costly; in fact, for a retrospective observational study, the cost might essentially be nothing. This makes 
it an acceptable method for studying the long-term effects of a remittive therapy such as an anti-TNF 
agent. Moreover, studying a treatment longitudinally allows for the assessment of drug survival, a 
proven surrogate marker for efficacy, as a primary outcome (Geborek, et al., 2002). 
29 
 
  The validity of drug survival as a surrogate outcome for drug efficacy can be justified based on 
the criteria delineated by Haynes et al. First, a surrogate outcome must be prognostic for its hard 
outcome (Haynes, et al., 2006). It has been demonstrated in previous studies comparing RCT and 
observational study data that withdrawal from antirheumatic drug therapy is largely due to lack of 
efficacy (Maetzel, et al., 1999; Hawley, et al., 1991). Secondly, changes in a surrogate outcome must 
predict corresponding changes in its hard outcome and, thirdly, effects of treatment on the surrogate 
outcome should explain effects of treatment on the hard outcome (Haynes, et al., 2006). These have 
both been demonstrated in previous studies which measured drug survival and changes in patient 
quality of life (QOL) concurrently. In their study, Heiberg et al show that AS patients survive longer on 
anti-TNF therapy than do RA patients, and that AS patients on anti-TNF therapy also show greater 
improvements in physical QOL scores (i.e. bodily pain and physical limitations) than RA patients on these 
drugs (Heiberg, et al., 2008). QOL was measured in this study using a 36-item Short Form Health Survey 
(SF-36), which is used clinically to assess treatment efficacy (Schur, et al., 2014). 
 A few longitudinal, observational studies have been done recently which examine the survival of 
anti-TNF agents in patients with inflammatory arthritis. One study found that the three major anti-TNF 
agents (infliximab, etanercept, and adalimumab) had similar drug survival among a group of patients 
with various forms of inflammatory arthritis (Duclos, et al., 2006). They also found that overall anti-TNF 
agent survival was significantly better in SpA patients (PsA, AS, and other spondyloarthropathies) than in 
RA patients (Duclos, et al., 2006). Another study found that concomitant MTX use is associated with 
longer anti-TNF survival in patients with RA or PsA (Heiberg, et al., 2008).  
These longitudinal studies do provide some insight into the use of TNF-α inhibition in 
inflammatory arthritis but more data are necessary. For instance, it would be helpful to know how each 
of the three major anti-TNF agents performs in each of RA, PsA, and AS. Head-to-head comparisons of 
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the anti-TNF agents, which are lacking in the current literature, are important for ascertaining 
differences in efficacy between monoclonal antibodies (i.e. infliximab and adalimumab) and synthetic 
receptors (i.e. etanercept), for example. Ascertaining the effects of potential confounding variables on 
anti-TNF performance (e.g. sex, age, and concomitant drug use) would also be very useful for guiding 
treatment decisions.  
Another area lacking sufficient research is the etiology of drug failure. It has been shown that 
arthritis patients who fail a course of anti-TNF therapy prematurely (<6 months of therapy) present 
initially with less synovial TNF-α expression than patients who respond to therapy (Tak, 2012). 
Conversely, in patients who fail anti-TNF therapy later on (>6 months of therapy), it has been shown that 
endogenous anti-drug antibodies are partly responsible for failure (Wolbink, et al., 2006). Thus, for 
prognostic purposes, it would be useful to know if any particular patient characteristics (e.g. sex, age, or 
smoking status) correlate with either a premature or delayed mechanism of drug failure. 
Finally, it would also be helpful to understand how well these drugs perform when given to 
patients who have already failed a course of anti-TNF treatment. There is evidence suggesting that the 
survival of the second course of anti-TNF treatment is significantly shorter than that of the first course 
for inflammatory arthritis patients (Duclos, et al., 2006). However, there are other sources which 
suggest that no significant difference exists between the survivals of the two courses (Heiberg, et al., 
2008; Hyrich, et al., 2007). Resolution of this disagreement would require an examination of the survival 
of both courses for each of the three diseases. Stratifying this analysis by diagnosis is particularly 
important given that the majority of previous studies have either focused exclusively on RA patients or 
analyzed all 3 diseases together.  
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1.4 Questions and Hypotheses 
 The primary purpose of the present study is to address these deficits in the medical literature. 
Using a longitudinal, observational study design, the following two questions will be answered.  
First, is real-life drug survival of the first course of anti-TNF therapy significantly different in 
patients with RA, PsA, or AS? Given the trends seen in existing studies, we hypothesize that anti-TNF 
survival will be significantly less among patients with RA than in patients with PsA or AS (Duclos, et al., 
2006; Carmona, et al., 2006; Heiberg, et al., 2008).  
Secondly, within each of these diagnoses, are there significant differences between the drug 
survivals of the first courses of infliximab, etanercept, and adalimumab? It is difficult to generate a 
hypothesis for this question due to a lack of data. However, there is evidence indicating that the three 
drugs have similar survivals among inflammatory arthritis patients in general (Duclos, et al., 2006).  
Both of these questions will be answered with adjustments for the following known 
confounders of anti-TNF agent survival: sex, age, smoking status (Wendling, et al., 2013), concomitant 
use of MTX, and concomitant use of prednisone. Also, for each treatment group identified, the 
proportions of patients discontinuing anti-TNF therapy for reasons of either inefficacy or adverse 
event(s) will be assessed. This will help us determine how useful drug survival is as a surrogate outcome 
for drug efficacy, and whether the incidence of adverse events decreases its usefulness. Finally, in an 
attempt to elucidate potential reasons for premature vs. delayed anti-TNF failure, the baseline variables 
of these two groups will be compared for any significant differences. 
A couple of secondary questions will be answered as well. First, in inflammatory arthritis 
patients overall, is there a significant difference between the drug survivals of the first and second 
courses of anti-TNF therapy? Since most of the evidence in the literature indicates either there is no 
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significant difference in survival between the two courses (Heiberg, et al., 2008; Hyrich, et al., 2007), or 
that the first course has a greater survival than the second (Greenberg, et al., 2012; Glintborg, et al., 
2013; Duclos, et al., 2006), we hypothesize that anti-TNF survival will be significantly less among patients 
taking their second course of anti-TNF therapy than those taking their first. 
Secondly, among patients taking a second course of anti-TNF therapy, is there a significant 
difference in drug survival among the 3 diagnoses and among the 3 different anti-TNF agents? This is 
another question which has not been adequately investigated in the literature to generate a meaningful 
hypothesis. Therefore, it is hypothesized that patterns of drug survival will be similar to what has been 
documented for patients taking a first course of anti-TNF therapy (i.e. decreased anti-TNF survival in RA 
vs. AS or PsA and similar survival among the 3 types of anti-TNF therapy). This question will be answered 
with adjustments for sex, age, smoking status, concomitant use of MTX, and concomitant use of 
prednisone. 
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Chapter 2 Methods 
2.1 Study Design and Setting 
 This was a retrospective study using the medical records of patients with inflammatory arthritis 
from two clinics. A retrospective design was chosen for the following reasons. First, because we did not 
have access to an ongoing prospective database for anti-TNF therapy in the study setting, the study 
questions could only be answered by gathering data retrospectively. Secondly, this was an efficient 
design with respect to data collection and cost. Finally, a retrospective design is advantageous because it 
eliminates study-driven changes in patient behavior.  
Patient data was gathered from two separate centers: one is the local rheumatology 
department at St. Clare’s Mercy Hospital (SCMH) in St. John’s, Newfoundland and Labrador (NL), Canada 
and the other is the rheumatology department at Toronto Western Hospital in Toronto. SCMH is the 
referral site for all rheumatology patients living in NL, serving a population of just over 500,000. Toronto 
Western Hospital is one of several hospitals serving rheumatology patients in the Toronto area, which 
has a population of over 5.1 million.  
The primary setting for the study was the St. John’s center. Five rheumatologists practiced in St. 
John’s at the time of this study (four practiced at SCMH) and access was provided to the patient data 
belonging to three of them. All three rheumatologists practiced in a similar, university setting and no 
referral bias was observed in the types of patients seen by each rheumatologist. We were able to collect 
data from RA, PsA, and AS patients seen by these physicians. 
All three major anti-TNF agents were available in NL at the time of this study but they were only 
covered by the provincial government since 2002 [via the NL Prescription Drug Plan (NLPDP)]. 
Furthermore, the NLPDP was initially biased towards covering etanercept due to cost. Thus, because 
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about 40% of patients on anti-TNF therapy in NL are covered by the NLPDP, we anticipated a larger 
quantity of St. John’s center patients to be using etanercept than either infliximab or adalimumab. 
The Toronto center was a secondary setting for this study and was only used to collect data 
from AS patients. All the data collected from this center belongs to one rheumatologist working in a 
university setting whose research and clinical practice focuses on AS. 
2.2 Selection of Patients and Data Collection 
 Patients were eligible for the present study if they had been diagnosed with RA, PsA, or AS and 
treated with one or more of the three TNF-α antagonists (i.e. infliximab, etanercept and adalimumab). 
All RA patients included met the new ACR/EULAR classification criteria; all PsA patients included met the 
CASPAR criteria; and all AS patients included met the ASAS criteria. No additional criteria were used to 
determine study eligibility. Diagnostic codes were not used. 
 In the St. John’s center, eligible patients were identified by exhaustively screening the files of 
patients seen by three out of the four rheumatologists practicing at SCMH. Once his/her eligibility was 
confirmed on screening, each patient was assigned a numerical code to ensure confidentiality. Since this 
screening was done over the summer of 2009, only patients who started their first anti-TNF prior to 
August 2009 were included in this study (i.e. patients starting any time prior to August 2009 (inclusive) 
were eligible).  
 Data collection for St. John’s center patients was done by the principal investigator (SH) from 
February 2010 to August 2010 (thus February 2010 was the latest date for recorded follow-up). All the 
necessary demographic and treatment information was gathered using a form designed specifically for 
the present study (Appendix A). The demographic and clinical data collected for each patient included 
sex, year of birth, height, weight, smoking status, rheumatic diagnosis, disease duration, and previous 
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medications. These particular variables were chosen based on their effect on the outcomes of similar 
studies. Sex, age, body mass index (BMI), and smoking status have all been shown to significantly alter 
the effectiveness of anti-TNF agents in inflammatory arthritis patients (Heiberg, et al., 2008). For each 
course of anti-TNF treatment, the following data was collected: the ranking of the anti-TNF agent (first, 
second, or third), the type of anti-TNF agent, its initial prescription date, which concomitant DMARDs 
and/or corticosteroids were prescribed at the time the anti-TNF treatment was initiated, and the date of 
treatment termination or of most recent follow-up. Concomitant medications were recorded due to 
their known influence on anti-TNF agent performance (Heiberg, et al., 2008; Duclos, et al., 2006). Also, if 
anti-TNF treatment was terminated, the reason was noted; reasons were classified as inefficacy, adverse 
event, or other (e.g., planning a pregnancy, financial reasons, etc.). The reason for treatment 
termination was not known in some cases, owing to the fact that there was no pre-existing protocol for 
collection of this information; the retrospective nature of this study relied heavily on the routine 
documentation practices of the rheumatologists involved. 
 In the Toronto center, patient screening and data collection were done by a group not directly 
involved in the present study. Screening at this center took place at approximately the same time as it 
did at the St. John’s center; data for patients who started their first anti-TNF after August 2009 were not 
included. All the required demographic and treatment information belonging to the Toronto center 
patients was electronically transferred to the study investigators and merged with the rest of the data 
set. One systematic issue with data collection here was missing concomitant DMARD and corticosteroid 
data for many of the Toronto AS patients (this is likely due to the reluctance to use DMARDs and 
prednisone in AS patients). This was addressed by adjusting the statistical analysis accordingly, as 
discussed below. 
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2.3 Statistical Analyses 
 The crude drug survival rates for each cohort were determined with Kaplan-Meier analyses, 
using the log rank test to test for significance between survival curves. For the first course of anti-TNF 
therapy, this was done to compare drug survival among the 3 diseases of interest, and to compare 
survival among the three anti-TNF s of interest within each disease. For the second course of anti-TNF 
therapy, this was done to compare drug survival among the 3 diseases, and to compare survival among 
the three anti-TNF s in the overall inflammatory arthritis population. Cox regression was then performed 
to assess the hazard ratios (HRs) for treatment termination for each cohort. This was done using 
adjustments for age, sex, smoking status, concomitant prednisone use, and concomitant MTX use; each 
of these variables was assigned as a covariate in the Cox regression model (except in the case of 
comparing anti-TNF survival exclusively in the AS patient population, where the concomitant prednisone 
and MTX covariates were omitted). The assumption of constant proportional hazards was assessed and 
held true for all covariates. 
Among the patients who failed their first course of anti-TNF therapy, the baseline variables of 
those who failed in ≤6 months were compared with those who failed in >6 months. Apart from age, 
which was compared using an independent samples t-test, all variables (diagnosis, type of anti-TNF 
agent, sex, smoking status, concomitant prednisone use, and concomitant MTX use) were compared 
using Pearson’s Chi-Square test.  
In order to compare drug survival times of the first and second courses of anti-TNF therapy 
among the cohort of patients who received both, a paired samples t-test was used.10 
                                                            
10 More robust forms of analysis such as Kaplan-Meier analysis and Cox regression could not be used in this 
instance as there were by definition no survivors in one of the groups being compared (i.e. the group taking their 
first course of therapy) 
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Using the data comparing first-course anti-TNF survival among the three diseases, the post hoc 
power of the study was evaluated. This was done using a log rank test statistic. 
A significance level of 5% was used in all analyses. Statistical analyses were performed with SPSS 
software, version 17.0 (SPSS, Chicago, IL). 
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Chapter 3 Results 
3.1 Patients 
A total of 332 patients were eligible for the analysis (160 AS patients, 58 PsA patients, and 114 
RA patients; Table 3.1). All patients were followed from the date they started their anti-TNF therapy to 
the date they stopped their therapy, or their date of most recent follow-up before February 2010. The 
earliest date of follow-up was June 1998. There was no loss to follow-up. 
Table 3.1: Demographic and clinical characteristics of all patients at baseline 
 RA (n=114, 34.3%) PsA (n=58, 17.5%) AS (n=160, 48.2%) p-value* 
Age, years ± SD 53.5 ± 11.1 45.9 ± 9.7 38.3 ± 12.0 0 
Female, no. (% within Dx) 95 (83.3) 26 (44.8) 32 (20.0) 0 
Smoker, no. (% within Dx) 20 (17.5) 8 (13.8) 49 (30.6) 0.006 
Concomitant Pred, no. (% 
within Dx) 
73 (64.0) 33 (56.9) N/A 0 
Concomitant MTX, no. (% 
within Dx) 
68 (59.6) 16 (27.6) N/A 0 
Infliximab, no. (% within Dx) 22 (19.3) 5 (8.6) 78 (48.8) 0 
Etanercept, no. (% within Dx) 61 (53.5) 34 (58.6) 52 (32.5) 0 
Adalimumab, no. (% within Dx) 31 (27.2) 19 (32.8) 30 (18.8) 0 
*p-values are for the overall comparison among the 3 groups 
As the p-values in Table 3.1 demonstrate, the three disease cohorts were significantly dissimilar with 
respect to every characteristic measured. RA patients were older on average than either PsA or AS 
patients and more RA patients were women whereas most PsA and AS patients were men. Etanercept 
was prescribed more heavily in RA and PsA patients whereas infliximab was the anti-TNF of choice in AS 
patients. Over half of the RA patients were taking either MTX or prednisone at the time they started 
their first anti-TNF. The same was true of PsA patients but for MTX only. Because this information was 
not available for a significant number of AS patients (namely those whose data came from the Toronto 
centre), it was not possible to assess how many of them were taking either prednisone or MTX. 
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However, the number of AS patients taking prednisone or MTX was estimated to be very low as neither 
is prescribed commonly for treating this disease. 
3.2 Statistical Analysis 
3.2.1 Survival of the First Course of anti-TNF Therapy 
a) Overall Anti-TNF Survival in AS vs. PsA vs. RA 
 Kaplan-Meier analysis was used to assess the differences in crude drug survival among the three 
diseases. The estimated mean drug survival times were 53.5, 35.9, and 42.4 months for AS, PsA, and RA, 
respectively (Table 3.2). The log rank test showed that the differences in drug survival between AS and 
RA (p = 0.028 at 95% confidence) and between AS and PsA (p = 0.045) were both statistically significant, 
but the difference in drug survival between RA and PsA (p = 0.712) was not significant (Table 3.3, Figure 
3.1). 
Table 3.2: Estimated mean first-course anti-TNF agent survival times for AS, PsA, and RA patients 
Dx 
Mean 
Estimate Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
AS 53.495 2.896 47.819 59.171 
PsA 35.851 2.984 30.001 41.700 
RA 42.382 3.286 35.942 48.821 
Overall 47.702 2.013 43.757 51.647 
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Table 3.3: Pairwise comparisons of first-course anti-TNF survival among AS, PsA, and RA patients 
 
Dx 
AS PsA RA 
 Chi-Square Sig. Chi-Square Sig. Chi-Square Sig. 
Log Rank (Mantel-Cox)          AS   4.036 .045 4.850 .028 
PsA 4.036 .045   .136 .712 
RA 4.850 .028 .136 .712   
 
 
 
Figure 3.1: First-course anti-TNF agent survival among AS, PsA, and RA patients 
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Table 3.4A: Adjusted hazard ratios for discontinuing first-course anti-TNF agents among AS, PsA, and RA (RA 
reference) 
 
B SE Wald df Sig. HR 
95.0% CI for HR 
 Lower Upper 
RA (reference)   .916 2 .633    
AS -.087 .235 .137 1 .711 .917 .579 1.453 
PsA .162 .234 .478 1 .489 1.176 .743 1.862 
 
 
Table 3.4B: Adjusted hazard ratios for discontinuing first-course anti-TNF agents among AS, PsA, and RA (AS 
reference) 
 
B SE Wald df Sig. HR 
95.0% CI for HR 
 Lower Upper 
AS (reference)   .916 2 .633    
PsA .249 .266 .877 1 .349 1.283 .762 2.160 
RA .087 .235 .137 1 .711 1.091 .688 1.728 
 
 After adjusting for age, sex, smoking status, anti-TNF agent type, concomitant MTX, and 
concomitant prednisone, the respective hazard ratios (HRs) and 95% confidence intervals (CIs) for 
treatment termination in AS and PsA patients versus RA patients were 0.92 (0.58-1.45) and 1.18 (0.74-
1.86; Table 3.4A). The HR for treatment termination in PsA versus AS patients was 1.28 (0.76-2.16; Table 
3.4B). The adjusted risk of anti-TNF treatment termination was not significantly different among the 
three arthritides. None of the covariates were found to be associated with treatment termination. 
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b) Etanercept vs. Adalimumab vs. Infliximab in AS patients 
 Kaplan-Meier analysis was done to assess the differences in crude drug survival among the three 
anti-TNF drugs within each diagnosis. In AS, the estimated mean drug survival times were 63.9, 54.2, and 
80.0 months for etanercept, adalimumab, and infliximab, respectively (Table 3.5). The log rank test 
showed that the differences in crude drug survival between etanercept and adalimumab (p = 0.652), 
etanercept and infliximab (p = 0.333), and adalimumab and infliximab (p = 0.820) were not statistically 
significant (Table 3.6, Figure 3.2). After adjusting for age, sex, and smoking status the respective HRs and 
95% CIs for treatment termination in AS patients taking etanercept and adalimumab versus those taking 
infliximab were 1.24 (0.66-2.33) and 1.14 (0.53-2.46; Table 3.7A). The HR and CI for treatment 
termination in AS patients taking adalimumab versus those taking etanercept was 0.92 (0.41-2.09; Table 
3.7B). The adjusted risk of treatment termination in AS was not significantly different among the three 
anti-TNF drugs. Of the covariates tested, only sex was found to be associated with treatment 
termination: the HR and CI for termination in males versus females was 0.51 (0.27-0.95). 
 
Table 3.5: Estimated mean first-course anti-TNF agent survival times for AS patients using etanercept, 
adalimumab, or infliximab 
Rx 
Mean 
 
Estimate Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
Etanercept 63.904 5.904 52.332 75.477 
Adalimumab 54.216 5.760 42.926 65.506 
Infliximab 80.003 5.708 68.815 91.191 
Overall 77.820 4.262 69.467 86.173 
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Table 3.6: Pairwise comparisons of first-course anti-TNF survival among AS patients using etanercept, 
adalimumab, or infliximab 
 
Rx 
Etanercept Adalimumab Infliximab 
 Chi-Square Sig. Chi-Square Sig. Chi-Square Sig. 
Log Rank  
(Mantel-Cox)          
Etanercept   .203 .652 .939 .333 
Adalimumab .203 .652   .052 .820 
Infliximab .939 .333 .052 .820   
 
 
 
Figure 3.2: First-course anti-TNF agent survival among AS patients using etanercept, adalimumab, or 
infliximab 
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Table 3.7A: Adjusted hazard ratios for discontinuing first-course anti-TNF agents among AS patients (infliximab 
reference) 
 
B SE Wald df Sig. HR 
95.0% CI for HR 
 Lower Upper 
male -.678 .319 4.508 1 .034 .508 .272 .949 
Infliximab (ref)   .456 2 .796    
Etanercept .214 .323 .440 1 .507 1.239 .658 2.332 
Adalimumab .133 .392 .115 1 .735 1.142 .529 2.464 
 
Table 3.7B: Adjusted hazard ratios for discontinuing first-course anti-TNF agents among AS patients (etanercept 
reference) 
 
B SE Wald df Sig. HR 
95.0% CI for HR 
 Lower Upper 
male -.678 .319 4.508 1 .034 .508 .272 .949 
Etanercept (ref)   .456 2 .796    
Adalimumab -.081 .418 .038 1 .846 .922 .407 2.092 
Infliximab -.214 .323 .440 1 .507 .807 .429 1.520 
 
c) Etanercept vs. Adalimumab vs. Infliximab in PsA patients 
 In Kaplan-Meier analysis of PsA patients, the estimated mean drug survival times were 35.4, 36.5, 
and 25.0 months for etanercept, adalimumab, and infliximab, respectively (Table 3.8). The log rank test 
showed that the differences in crude drug survival between etanercept and adalimumab (p = 0.601), 
etanercept and infliximab (p = 0.685), and adalimumab and infliximab (p = 0.559) were not statistically 
significant (Table 3.9, Figure 3.3). After adjusting for age, sex, smoking status, concomitant MTX, and 
concomitant prednisone, the respective HRs and 95% CIs for treatment termination in PsA patients taking 
etanercept and adalimumab versus those taking infliximab were 0.77 (0.18-3.34) and 0.59 (0.12-2.94; Table 
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3.10A). The HR and CI for treatment termination in PsA patients taking adalimumab versus those taking 
etanercept was 0.77 (0.31-1.95; Table 3.10B). The adjusted risk of treatment termination in PsA was not 
significantly different among the three anti-TNF drugs. None of the covariates were found to be associated 
with treatment termination. 
Table 3.8: Estimated mean first-course anti-TNF agent survival times for PsA patients using etanercept, 
adalimumab, or infliximab 
Rx 
Mean 
 
Estimate Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
Etanercept 35.448 3.514 28.560 42.335 
Adalimumab 36.454 4.736 27.171 45.738 
Infliximab 25.000 6.627 12.011 37.989 
Overall 35.851 2.984 30.001 41.700 
 
 
 
 
 
Table 3.9: Pairwise comparisons of first-course anti-TNF survival among PsA patients using etanercept, 
adalimumab, or infliximab 
 
Rx 
Etanercept Adalimumab Infliximab 
 Chi-Square Sig. Chi-Square Sig. Chi-Square Sig. 
Log Rank  
(Mantel-Cox)          
Etanercept   .273 .601 .164 .685 
Adalimumab .273 .601   .342 .559 
Infliximab .164 .685 .342 .559   
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Figure 3.3: First-course anti-TNF agent survival among PsA patients using etanercept, adalimumab, or 
infliximab 
 
Table 3.10A: Adjusted hazard ratios for discontinuing first-course anti-TNF agents among PsA patients (infliximab 
reference) 
 
B SE Wald df Sig. HR 
95.0% CI for HR 
 Lower Upper 
Infliximab (ref)   .505 2 .777    
Etanercept -.268 .752 .127 1 .722 .765 .175 3.339 
Adalimumab -.526 .819 .413 1 .520 .591 .119 2.941 
 
47 
 
 
 
 
 
 
 
Table 3.10B: Adjusted hazard ratios for discontinuing first-course anti-TNF agents among PsA patients (etanercept 
reference) 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 Lower Upper 
Etanercept (ref)   .505 2 .777    
Adalimumab -.258 .472 .299 1 .584 .772 .306 1.949 
Infliximab .268 .752 .127 1 .722 1.307 .299 5.704 
 
d) Etanercept vs. Adalimumab vs. Infliximab in RA patients 
 In Kaplan-Meier analysis of RA patients, the estimated mean drug survival times were 48.9, 54.0, and 
63.3 months for etanercept, adalimumab, and infliximab, respectively (Table 3.11). The log rank test showed 
that the difference in crude drug survival between etanercept and adalimumab (p = 0.010) was statistically 
significant, but the differences in survival between etanercept and infliximab (p = 0.178), and adalimumab 
and infliximab (p = 0.227) were not statistically significant (Table 3.12, Figure 3.4). Initially, it may seem 
counterintuitive that adalimumab (mean survival = 54.0 months), and not infliximab (mean survival = 63.3 
months), had a significantly greater survival than etanercept (mean survival = 48.9 months). However, the log 
rank test compares survival distributions and not survival means, allowing it to correct for drug survival data 
which may be deceptively inflated (i.e. in the case of infliximab, which has been prescribed for RA several 
years longer than adalimumab, allowing a greater mean survival for infliximab vs. adalimumab in the present 
study but not necessarily a superior survival distribution). After adjusting for age, sex, smoking status, 
concomitant MTX, and concomitant prednisone, the respective HRs and 95% CIs for treatment termination in 
RA patients taking etanercept and adalimumab versus those taking infliximab were 1.60 (0.79-3.23) and 0.54 
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(0.20-1.49; Table 3.13A). The HR and CI for treatment termination in RA patients taking adalimumab versus 
those taking etanercept was 0.34 (0.14-0.80; Table 3.13B). The adjusted risk of treatment termination was 
only significantly lower in RA patients taking adalimumab versus those taking etanercept.  None of the 
covariates were found to be associated with treatment termination. 
Table 3.11: Estimated mean first-course anti-TNF agent survival times for RA patients using etanercept, 
adalimumab, or infliximab 
Rx 
Mean 
 
Estimate Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
Etanercept 48.896 7.333 34.523 63.269 
Adalimumab 54.012 5.113 43.990 64.034 
Infliximab 63.323 11.220 41.332 85.313 
Overall 61.506 6.061 49.626 73.386 
 
 
 
 
Table 3.12: Pairwise comparisons of first-course anti-TNF survival among RA patients using etanercept, 
adalimumab, or infliximab 
 
Rx 
Etanercept Adalimumab Infliximab 
 Chi-Square Sig. Chi-Square Sig. Chi-Square Sig. 
Log Rank  
(Mantel-Cox)          
Etanercept   6.714 .010 1.818 .178 
Adalimumab 6.714 .010   1.462 .227 
Infliximab 1.818 .178 1.462 .227   
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Figure 3.4: First-course anti-TNF agent survival among RA patients using etanercept, adalimumab, or 
infliximab 
Table 3.13A: Adjusted hazard ratios for discontinuing first-course anti-TNF agents among RA patients (infliximab 
reference) 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 Lower Upper 
Infliximab (ref)   6.841 2 .033    
Etanercept .469 .359 1.699 1 .192 1.598 .790 3.232 
Adalimumab -.617 .518 1.418 1 .234 .539 .195 1.490 
 
Table 3.13B: Adjusted hazard ratios for discontinuing first-course anti-TNF agents among RA patients (etanercept 
reference) 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 Lower Upper 
Etanercept (ref)   6.841 2 .033    
Adalimumab -1.086 .441 6.052 1 .014 .338 .142 .802 
Infliximab -.469 .359 1.699 1 .192 .626 .309 1.266 
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e) Inefficacy vs. Adverse Events in all patients 
 Table 3.14 shows the frequencies for the two chief reasons for first anti-TNF discontinuation 
among the disease and treatment groups identified. These reasons were lack of efficacy or one or more 
adverse events such as infection or malignancy. For some disease and treatment groups, the 
proportions discontinuing due to lack of efficacy or adverse events were similar. However, in the case of 
PsA patients, 21 stopped their anti-TNF due to lack of efficacy whereas only 3 stopped due to adverse 
events. Another imbalance is in the case of RA patients, with 32 quitting their anti-TNF due to lack of 
efficacy and 12 due to adverse events. Also, for all patients taking etanercept, 53 discontinued due to 
lack of efficacy and only 10 discontinued due to adverse events. Finally, an overall comparison of the 
two reasons for discontinuation in the entire first anti-TNF study population revealed that lack of 
efficacy was more of an issue than adverse events, with 74 quitting due to the former and 34 due to the 
latter. Notably, for 26 of the 134 total patients who discontinued their first course of anti-TNF therapy 
(i.e. 19%), there was no reason noted for anti-TNF discontinuation. 
Table 3.14: Frequencies for reasons for discontinuation (D/C) by diagnosis and anti-TNF agent 
 Reason for D/C AS PsA RA Total 
Etanercept Adverse event(s) 3 1 6 10 
Inefficacy 10 17 26 53 
Unknown 5 3 4 12 
Adalimumab Adverse event(s) 5 1 3 9 
Inefficacy 3 4 3 10 
Unknown 1 1 0 2 
Infliximab Adverse event(s) 11 1 3 15 
Inefficacy 8 0 3 11 
Unknown 7 1 4 12 
Total AE,IE,UK 19,21,13 3,21,5 12,32,8 134 
*AE: adverse event(s), IE: inefficacy, UK: unknown 
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f) Primary vs. Secondary Non-responders among all patients 
 To further explore the causes of premature anti-TNF discontinuation, the 134 patients who 
failed their first anti-TNF were split into primary non-responders (anti-TNF failure in ≤6 months) and 
secondary non-responders (anti-TNF failure in >6 months). These two groups were then compared on 
various baseline variables to see if any were significantly different (Table 3.15). Age was compared using 
an independent samples t-test. Diagnosis, anti-TNF type, sex, smoking status, concomitant MTX use, and 
concomitant prednisone use were compared using Pearson’s Chi-Square test. No tested variables were 
found to be significantly different between the two groups. 
 
Table 3.15: Comparison of baseline variables between primary non-responders and secondary non-
responders to anti-TNF therapy 
Baseline Variable (p-value) Primary Non-Responder* 
(n=43) 
Secondary Non-Responder* 
(n=91) 
Age (p=0.528) 44.23 45.70 
Dx (p=0.207)                               AS 
PsA 
RA 
21 
6 
16 
32 
23 
36 
Rx (p=0.226)                 Etanercept 
Adalimumab 
Infliximab 
23 
10 
10 
52 
11 
28 
Sex (p=0.969)                               M 
F 
20 
23 
42 
49 
Smoker (p=0.239)                        N 
Y 
31 
12 
73 
17 
MTX (p=0.308)                              N 
Y 
18 
18 
44 
29 
Prednisone (p=0.635)                 N 
Y 
17 
19 
38 
35 
*Primary non-responder: anti-TNF failure in ≤6 months, Secondary non-responder: anti-TNF failure in 
>6 months 
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3.2.2 Survival of the Second Course of anti-TNF Therapy 
a) First vs. Second Course of Anti-TNF Therapy in patients who tried both 
 In the 98 patients who failed their first anti-TNF agent and were placed on a second agent, crude 
drug survival was compared between the two courses using a paired samples t-test (Table 3.16). Mean 
drug survival for the first course was 18.1 months and that for the second course was 19.8 months (p = 
0.443; Table 3.17). There was no significant difference in drug survival between first and second courses 
of anti-TNF therapy. 
Table 3.16: Mean drug survival times for patients who took two courses of anti-TNF therapy  
Anti-TNF Course N Mean Survival (months) SD 
1st Course 98 18.10 16.047 
2nd Course 98 19.83 16.271 
 
Table 3.17: Paired samples t-test comparing first vs second course of anti-TNF therapy 
 Paired Differences 
t df 
Sig. (2-
tailed) Mean SD 
Std. 
Error of 
Mean 
95% CI of the 
difference 
Lower Upper 
1st course – 
2nd course 
-1.724 22.184 2.241 -6.172 2.723 -0.770 97 0.443 
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b) Overall anti-TNF survival in AS vs. PsA vs. RA 
 Kaplan-Meier analysis was used to assess the differences in crude second-course anti-TNF 
survival among the three diseases. The estimated mean drug survival times were 37.0, 44.4, and 34.0 
months for AS, PsA, and RA, respectively (Table 3.18). The log rank test showed that the difference in 
crude drug survival between PsA and RA (p = 0.029) was statistically significant, but the differences in 
survival between PsA and AS (p = 0.139), and AS and RA (p = 0.413) were not statistically significant 
(Table 3.19, Figure 3.5). After adjusting for age, sex, smoking status, anti-TNF agent type, concomitant 
MTX, and concomitant prednisone, the respective HRs and 95% CIs for treatment termination in AS and 
PsA patients versus RA patients were 0.62 (0.28-1.40) and 0.42 (0.19-0.93; Table 3.20A). The HR for 
treatment termination in PsA versus AS patients was 0.67 (0.25-1.81; Table 3.20B). The adjusted risk of 
treatment termination was only significantly lower in PsA patients versus RA patients. None of the covariates 
were found to be associated with treatment termination. 
Table 3.18: Estimated mean second-course anti-TNF agent survival times for AS, PsA, and RA patients 
Dx 
Mean 
Estimate Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
AS 36.952 5.596 25.984 47.921 
PsA 44.352 5.429 33.710 54.994 
RA 33.980 6.224 21.782 46.178 
Overall 41.929 4.463 33.182 50.667 
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Table 3.19: Pairwise comparisons of second-course anti-TNF survival among AS, PsA, and RA patients 
 
Dx 
AS PsA RA 
 Chi-Square Sig. Chi-Square Sig. Chi-Square Sig. 
Log Rank (Mantel-Cox)          AS   2.189 .139 .670 .413 
PsA 2.189 .139   4.766 .029 
RA .670 .413 4.766 .029   
 
 
 
 
 
Figure 3.5: Second-course anti-TNF agent survival among AS, PsA, and RA patients 
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Table 3.20A: Adjusted hazard ratios for discontinuing second-course anti-TNF agents among AS, PsA, and RA (RA 
reference) 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 Lower Upper 
RA (reference)   4.956 2 .084    
AS -.474 .412 1.326 1 .250 .622 .278 1.395 
PsA -.871 .410 4.524 1 .033 .418 .187 .934 
 
 
Table 3.20B: Adjusted hazard ratios for discontinuing second-course anti-TNF agents among AS, PsA, and RA (AS 
reference) 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 Lower Upper 
AS (reference)   4.956 2 .084    
PsA -.397 .506 .616 1 .433 .672 .249 1.812 
RA .474 .412 1.326 1 .250 1.607 .717 3.601 
 
 
c) Etanercept vs. Adalimumab vs. Infliximab in all patients 
Kaplan-Meier analysis was used to compare the crude second-course anti-TNF survival of the 
three anti-TNF agents in the entire inflammatory arthritis population. The estimated mean drug survival 
times were 35.2, 34.0, and 42.8 months for etanercept, adalimumab, and infliximab, respectively (Table 
3.21). The log rank test showed that the differences in crude drug survival between etanercept and 
adalimumab (p = 0.67), etanercept and infliximab (p = 0.91), and adalimumab and infliximab (p = 0.74) were 
not statistically significant (Table 3.22, Figure 3.6). After adjusting for age, sex, smoking status, concomitant 
MTX, and concomitant prednisone, the respective HRs and 95% CIs for treatment termination in patients 
taking etanercept and adalimumab versus those taking infliximab were 0.83 (0.26-2.61) and 1.32 (0.51-3.41; 
Table 3.23A). The HR and CI for treatment termination in patients taking adalimumab versus those taking 
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etanercept was 1.59 (0.69-3.65; Table 3.23B). The adjusted risk of treatment termination in the entire 
inflammatory arthritis population was not significantly different among the three anti-TNF drugs. None of 
the covariates were found to be associated with treatment termination. 
 
 
Table 3.21: Estimated mean second-course anti-TNF agent survival times for inflammatory arthritis patients 
using etanercept, adalimumab, or infliximab 
Rx 
Mean 
Estimate Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
Etanercept 35.175 6.245 22.934 47.415 
Adalimumab 34.001 3.964 26.232 41.770 
Infliximab 42.845 10.589 22.090 63.600 
Overall 41.929 4.463 33.182 50.677 
 
 
 
 
Table 3.22: Pairwise comparisons of second-course anti-TNF survival among inflammatory arthritis patients 
using etanercept, adalimumab, or infliximab 
 
Rx 
Etanercept Adalimumab Infliximab 
 Chi-Square Sig. Chi-Square Sig. Chi-Square Sig. 
Log Rank (Mantel-Cox)          Etanercept   .177 .674 .014 .905 
Adalimumab .177 .674   .110 .740 
Infliximab .014 .905 .110 .740   
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Figure 3.6: Second-course anti-TNF agent survival among inflammatory arthritis patients using 
etanercept, adalimumab, or infliximab 
 
 
 
Table 3.23A: Adjusted hazard ratios for discontinuing second-course anti-TNF agents among inflammatory arthritis 
patients (infliximab reference) 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 Lower Upper 
Infliximab (ref)   1.342 2 .511    
Etanercept -.190 .586 .105 1 .746 .827 .262 2.610 
Adalimumab .274 .486 .317 1 .573 1.315 .507 3.411 
58 
 
 
Table 3.23B: Adjusted hazard ratios for discontinuing second-course anti-TNF agents among inflammatory arthritis 
patients (etanercept reference) 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 Lower Upper 
Etanercept (ref)   1.342 2 .511    
Adalimumab .464 .423 1.199 1 .273 1.590 .693 3.645 
Infliximab .190 .586 .105 1 .746 1.209 .383 3.815 
 
 
3.2.3 Post Hoc Power Analysis 
 In order to assess the statistical power of the study, a post hoc power analysis was done using 
the data comparing overall first-course anti-TNF survival among the three diseases. The results show 
that only the comparison of anti-TNF survival between AS and PsA was adequately powered at 0.913 
(Table 3.22). Since the statistical power of both the AS-RA and PsA-RA comparisons was less than 0.80 
and thus underpowered, the results of these comparisons must be interpreted with caution. 
Table 3.24: Post hoc power analysis of first anti-TNF agent survival among AS, PsA, and RA patients 
Comparison Statistical Power 
AS vs. PsA 0.913 
AS vs. RA 0.639 
PsA vs. RA 0.248 
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Chapter 4 Discussion 
4.1 Longitudinal, Observational Studies vs. RCTs for the study of anti-TNF Therapy in Inflammatory 
Arthritis 
 TNF-α antagonists represent the most advanced line of therapy for inflammatory rheumatic 
disease. Although they are relatively new and very expensive, they are still widely prescribed to arthritis 
patients; those with more severe disease are particularly reliant upon these drugs. For these reasons, 
the efficacy and safety profiles of these drugs are currently topical in medical research and have 
generated a great deal of studies. The majority of these studies have been RCTs. For example, a 2004 
RCT investigated the efficacy and safety of adalimumab in RA patients over a six-month period (van de 
Putte, et al., 2004). Similar RCTs were done to examine etanercept in RA (Keystone, et al., 2004), 
infliximab in AS (van der Heijde, et al., 2005), adalimumab in PsA (Mease, et al., 2005), and every other 
possible TNF-α antagonist-inflammatory arthritis combination.  
While these studies are useful for accurately measuring drug effects and minimizing study bias, 
they often have limited generalizability and thus do not account for many real-life patient experiences. 
For instance, RCTs often have strict inclusion criteria in order to generate a homogeneous study 
population. This helps the RCT to demonstrate a more uniform response to the intervention, but the 
external validity of the trial suffers as a result of this homogeneity. A common example of this problem 
among RCTs examining inflammatory arthritis is the tendency to include only those patients whose 
disease activity scores are very elevated. A 2003 study illustrated this by examining a 146-patient cohort 
with longstanding, active, routinely managed RA to determine which proportion met each of the disease 
activity score criteria most commonly used among RCTs conducted with RA patients (i.e. swollen joint 
count >6, tender joint count >6, erythrocyte sedimentation rate >28 mm/h, and morning stiffness >45 
min). The study found that less than half of the cohort met each of the criteria and less than 10% met all 
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of them (Sokka, et al., 2003). Other characteristics commonly found in RCTs that reduce their external 
validity are the exclusion of patients with significant comorbidities (Keystone, et al., 2004), and a 
heightened frequency of patient assessment which is not feasible in a normal clinical setting. Another 
problem that predominates in these experimental studies is the recruitment of patients who cannot pay 
for their treatment and are thus particularly willing to take the study drug, which is often free of charge 
for them. Being especially incentivized to remain in the study, these patients may inflate the efficacy of 
the study drug. 
There have been a few studies which address these issues (Heiberg, et al., 2008; Duclos, et al., 
2006). These observational studies lack the often tight exclusion criteria of RCTs. Such studies might, for 
example, select all the arthritis patients who are treated with anti-TNF agents at a particular clinic in 
order to produce a highly generalizable study population. This population would likely consist of patients 
with a broad range of disease activity scores, a wide variety of comorbidities, and an overall realistic 
frequency of assessment. Also, since in an observational study the provision of treatment is outside the 
investigator’s control, these patients would presumably only use an anti-TNF agent as long as it is 
effective. Thus the number of patients who cannot pay for and/or have limited access to alternative 
treatment would be minimized. Heiberg et al’s 2008 study selected its patient population in just this 
fashion: they included all RA, PsA, and AS patients seen in five Norwegian rheumatology departments 
from 2000 onward who were treated with an anti-TNF agent (Heiberg, et al., 2008).  
A further criticism of the RCT approach in studies of inflammatory arthritis is the length of the 
follow-up period: many of the prominent RCTs investigating anti-TNF agents in arthritis last no longer 
than 24 weeks (Antoni, et al., 2005; Mease, et al., 2004; van der Heijde, et al., 2006). While this may be 
sufficient time to assess the drugs’ efficacy under optimal circumstances, it is not long enough to assess 
how the drugs perform under average circumstances, i.e. their effectiveness (Bombardier, et al., 1999). 
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The wide range of arthritis patients’ disease activity, compliance, and comorbidities seen in real-life 
conditions makes assessing drug effectiveness using an RCT particularly challenging. Moreover, the very 
nature of anti-TNF agents as remittive therapies11 for chronic, inflammatory arthritis makes studying 
them in the short term difficult. A longitudinal, observational study would therefore be better suited to 
this purpose. For example, in their observational study Heiberg et al observed their patients for an 
entire year, assessing patients’ response to treatment at 3, 6 and 12 months (Heiberg, et al., 2008). 
However, instead of relying on a scoring system like the ACR20 to assess treatment efficacy, their 
longitudinal study design allowed them to assess the survival rates of anti-TNF agents in patients as their 
primary outcome.  
Drug survival is not only an easily measured outcome, but also serves as a proven surrogate 
marker for a drug’s efficacy (Geborek, et al., 2002). Several longitudinal studies have been done to 
examine the survival of anti-TNF drugs in inflammatory rheumatic disease. In their study of 770 patients 
with various forms of inflammatory arthritis, Duclos et al found that the three major anti-TNF agents had 
similar drug survival over a three-year period (Duclos, et al., 2006). They also found that overall anti-TNF 
agent survival was significantly better in SpA patients than in RA patients, and significantly better for 
patients on their first course of anti-TNF treatment than those on their second or third course (Duclos, 
et al., 2006). This finding was echoed in another study, which additionally concluded that a higher rate 
of adverse events in RA patients using anti-TNF agents is partially responsible for the reduced drug 
survival seen in that disease (Carmona, et al., 2006). Heiberg et al’s one-year study generated similar 
results and also found that concomitant MTX is associated with significantly better anti-TNF agent 
survival in RA and PsA patients (Heiberg, et al., 2008). 
 
                                                            
11 A remittive therapy is one which is designed to promote remission of a disease 
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4.2 Explanation of the Results 
 The present study used a longitudinal, observational design to assess and compare drug survival 
in several different groups of subjects. The subjects were categorized based on two principal variables: 
inflammatory arthritis type and anti-TNF drug type. This categorization, along with the inclusion of 
several confounding variables, allowed us to determine which diseases and drugs were associated with 
longer drug survival and thus greater efficacy. Thus, the key purpose of this study was to both build 
upon and deconstruct the findings of the aforementioned observational studies. Previous studies have 
typically compared generalized anti-TNF agent survival among the three arthritides or, conversely, 
compared survival of each anti-TNF agent in a generalized arthritis population. This study aimed to 
elucidate the effect that each drug and disease exerts on drug survival by comparing all combinations of 
these two variables. 
4.2.1 Survival of the First Course of anti-TNF Therapy 
a) Overall Anti-TNF Survival in AS vs. PsA vs. RA 
 When the study subjects were divided only by disease type and drug survival was compared, 
crude Kaplan-Meier analysis revealed the average first-course anti-TNF agent survival for AS patients 
was significantly longer than that of either RA patients or PsA patients. This finding is similar to those of 
other studies in the literature. For instance, Duclos et al found that the anti-TNF agent survival was 
significantly greater for SpA patients than it was for RA patients (HR of 1.60 for anti-TNF agent survival). 
While their study did not break down the SpA classification further for analysis purposes, it is suggested 
that the majority of their SpA patients may have had AS (166 had axial disease, 64 had peripheral 
disease, and 60 had PsA). Carmona et al had a similar result when comparing SpA to RA (HR of 0.66 for 
anti-TNF agent discontinuation) except their SpA cohort was approximately 50% AS patients and 50% 
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PsA patients. Heiberg et al’s results also support this finding to a degree. Although their patients are 
only followed for a year, AS patients were found be at a significantly lesser risk of discontinuing their 
anti-TNF therapy than RA patients (HR of 0.66 for anti-TNF discontinuation). No such difference was 
found in that study between AS patients and PsA patients. 
 The superiority of drug survival in AS patients observed in the crude analysis was not observed 
once adjustments were made for several covariates (i.e. no significant HRs were found). Furthermore, 
no covariate contributed significantly to treatment termination. This has not been the case in other 
similar studies. Duclos et al found that concomitant DMARD (including MTX) decreased drug survival (HR 
of 0.70 for anti-TNF agent survival). In contrast, Heiberg et al found that concomitant MTX increased 
drug survival (HR of 0.53 for anti-TNF agent discontinuation). Also, Heiberg et al and Carmona et al both 
found that female patients were more likely than their male counterparts to discontinue an anti-TNF 
agent (HRs of 1.51 and 1.27 respectively for anti-TNF agent discontinuation). 
 Although we were not able to demonstrate a significant effect in the Cox regression analysis, it 
is clear from the Kaplan-Meier analysis and corroborated by other studies that AS patients tend to have 
superior anti-TNF drug survival. This may be due to increased efficacy of anti-TNF therapy in these 
patients but other potential reasons need to be considered. For example, it has been shown that once 
AS patients with axial disease have failed to respond to therapy with NSAIDs, the only effective 
treatment for them is anti-TNF therapy (Zochling, et al., 2006). This is in contrast to PsA and RA patients, 
who have several DMARDs available to them should NSAID therapy fail. Thus the increased drug survival 
observed in AS patients may be confounded by those patients’ lack of effective treatment alternatives. 
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b) Etanercept vs. Adalimumab vs. Infliximab in AS patients 
 When AS patients were analyzed separately and survival of the 3 types of anti-TNF therapy were 
compared, both crude Kaplan-Meier analysis and Cox proportional hazards modeling found no 
significant differences between the survivals of each drug. This result correlates well with the findings of 
pre-existing RCTs. For instance, in their systematic review of 9 RCTs comparing various anti-TNF agents 
(2 studies with adalimumab, 2 with infliximab, and 5 with etanercept) against placebo in 1611 AS 
patients, McLeod et al were unable to distinguish between the efficacies of the 3 agents (McLeod, et al., 
2007). A comparison of 3 more RCTs evaluating the efficacy of each of the 3 anti-TNF agents in AS 
patients somewhat corroborates this finding, with perhaps a slight trend towards an increased efficacy 
for infliximab and a decreased efficacy for adalimumab, i.e. one RCT found that 61% of AS patients 
treated with infliximab reached an ASAS20 after 24 weeks (van der Heijde, et al., 2005), another found 
that 57% treated with etanercept achieved this goal (Davis, et al., 2003), and another found that 51% 
treated with adalimumab achieved it (van der Heijde, et al., 2006). This trend is also observable in the 
results of the present study, with AS patients taking infliximab surviving for 80.0 months, those taking 
etanercept surviving for 63.9 months, and those taking adalimumab surviving for 54.2 months. It should 
be noted, however, that cross study comparisons are inherently difficult to interpret and vulnerable to 
considerable confounding. Thus these comparisons should be interpreted with caution. 
 One significant finding in the analysis of the AS subpopulation was that males were 50.8% as 
likely as females to discontinue anti-TNF therapy. This is consistent with the findings of Heiberg et al and 
Carmona et al, who found that being female predisposed to treatment termination in a generalized 
inflammatory arthritis population (Carmona, et al., 2006; Heiberg, et al., 2008). Glintborg et al had a 
similar finding when they examined AS patients in the Danish DANBIO registry, which includes >90% of 
adults in that country treated with biologics due to rheumatic disease in routine care (Glintborg, et al., 
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2013). This 1436-patient cohort (25% female) was then subdivided into patients who had only been 
treated with one biologic agent (“non-switchers”) and those who had received 2 or more courses of 
biologic therapy (“switchers”). They reported that women constituted only 22% of non-switchers but 
33% of switchers, a statistically significant finding. Furthermore, once switchers had switched to a 
second biologic agent, male gender was a significant predictor of longer drug survival (HR of 1.76). 
c) Etanercept vs. Adalimumab vs. Infliximab in PsA patients 
 In the separate analysis of PsA patients, Kaplan-Meier analysis and Cox proportional hazards 
modeling revealed no significant differences between the survivals of each of the 3 anti-TNF agents. This 
is also reflected in similar studies found in the literature: an RCT examining PsA patients treated with 
infliximab found that 54% reached an ACR20 after 24 weeks (Antoni, et al., 2005), another RCT found 
that 50% of PsA patients treated with etanercept reached an ACR 20 after 24 weeks (Mease, et al., 
2004), and a third RCT found that 57% of PsA patients treated with adalimumab reached an ACR20 after 
24 weeks (Mease, et al., 2005). A meta-analysis which indirectly compared the findings of 6 RCTs 
examining anti-TNF therapy in PsA patients (2 examining etanercept, 2 examining adalimumab, and 2 
examining infliximab) also corroborates this finding of equivalence (Thorlund, et al., 2012). Their 
outcomes, relative risk (RR) of therapeutic response based on PsA Response Criteria (PsARC) and mean 
change in baseline health assessment questionnaire (HAQ) score, were not significantly different among 
the 3 anti-TNF agents (Thorlund, et al., 2012). They also compared the 3 agents on the outcome of mean 
change in baseline psoriasis area and severity index (PASI) score. All 3 agents were statistically 
equivalent for this outcome as well (Thorlund, et al., 2012). 
 In the Cox model of anti-TNF agent survival in PsA patients no covariates were found to 
contribute significantly to treatment termination. In contrast, Glintborg et al have demonstrated that 
anti-TNF agent survival is significantly reduced in female PsA patients (HR of 1.42 for anti-TNF 
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discontinuation) and in PsA patients not taking concomitant MTX (HR of 1.37) (Glintborg, et al., 2011). 
The latter finding is echoed in another study comparing anti-TNF monotherapy with anti-TNF plus MTX 
therapy in PsA patients (Heiberg, et al., 2008).  
d) Etanercept vs. Adalimumab vs. Infliximab in RA patients 
 When RA patients were analyzed separately, both Kaplan-Meier crude drug survival analysis and 
Cox proportional hazards modeling showed that drug survival was superior in RA patients taking 
adalimumab compared to those taking etanercept. However, an indirect comparison of 3 RCTs 
examining anti-TNF therapy in RA patients gave markedly different results: one study found that 50% of 
RA patients treated with infliximab plus MTX reached an ACR20 after 30 weeks (Maini, et al., 1999), 
another study found that 75% of RA patients treated with etanercept reached an ACR20 after 12 weeks 
(Moreland, et al., 1997), and a third study found that only 46% of RA patients treated with adalimumab 
reached an ACR20 after 26 weeks (van de Putte, et al., 2004). A review of 3 more RCTs found altogether 
different results as well: the percentages of RA patients reaching ACR20 at 6 months were 92%, 63%, 
and 78% with infliximab, adalimumab, and etanercept, respectively (Jin, et al., 2010). Finally, there have 
also been studies which conclude there are no significant differences in effectiveness between 
etanercept, adalimumab, and infliximab for the treatment of RA (Mendoza, et al., 2010; Markenson, et 
al., 2011; Greenberg, et al., 2012). One was a retrospective study of a large, 5-year observational registry 
of RA patients. Investigators used one-year drug survival as their primary outcome and found that all 3 
anti-TNF agents performed very similarly (persistence rates of 51% for etanercept, 48% for adalimumab, 
and 51% for infliximab) (Markenson, et al., 2011). 
 The present study found that none of the covariates tested (i.e. age, sex, smoking status, 
concomitant MTX/prednisone) had a significant effect on anti-TNF agent survival in RA patients. This has 
not been the case in several other studies in the literature, however. The addition of MTX to anti-TNF 
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therapy has previously been found to significantly increase drug survival in RA patients (Heiberg, et al., 
2008; Hyrich, et al., 2006), whereas older age and concomitant prednisone have been shown to 
decrease drug survival (Hetland, et al., 2010). Smoking has also been reported to decrease efficacy and 
drug survival in RA patients taking infliximab (Hyrich, et al., 2006). 
e) Inefficacy vs. Adverse Events in all patients 
 In order to further elucidate how each disease and drug affects anti-TNF survival in arthritis 
patients, and to assess the validity of drug survival as a marker for drug efficacy, a brief analysis was 
done to compare the different reasons for first anti-TNF discontinuation among all the main study 
groups. The reasons for discontinuation were assigned to two broad categories: drug inefficacy or 
adverse events, e.g. malignancy or infection. The results indicated that, in the overall study population, 
inefficacy was cited more than twice as often as intolerance as the reason for anti-TNF discontinuation. 
This result was echoed in a similar study which found that after 36 months of observation, 53.5% of a 
large population of inflammatory arthritis patients taking anti-TNF therapy had discontinued treatment 
due to inefficacy; only 16% of the population had discontinued due to intolerance after 36 months 
(Duclos, et al., 2006). When the results of the present study are broken down by drug and disease, the 
findings are similar to the overall result: lack of efficacy explains more of treatment discontinuation than 
do adverse events. For example, among patients in the study whose first discontinued anti-TNF was 
etanercept, there were more than five times as many failures due to lack of efficacy than there were 
due to adverse events. Thus, there appears to be some evidence in this study and elsewhere in the 
literature that inflammatory arthritis patients who fail anti-TNF therapy tend to do so because the drug 
is not efficacious for them, a finding which validates the use of drug survival as a marker for drug 
efficacy. However, it must be noted that a considerable number of patients in the present study (19% of 
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all first anti-TNF terminations) had no reason reported for treatment termination, a finding which casts 
some uncertainty on the use of the drug survival outcome. 
f) Primary vs. Secondary Non-responders among all patients 
 An additional analysis was done to assess whether any of the patients’ baseline variables were 
associated with a dichotomous drug survival outcome: anti-TNF failure before or after 6 months. This 
outcome denotes the difference between primary and secondary non-responders to anti-TNF 
treatment. The rationale for this distinction stems from research indicating that patients who respond 
12-16 weeks after treatment initiation (i.e. primary responders) tend to present initially with increased 
synovial TNF expression, increased synovial lymphoid aggregates, as well as increases in other 
inflammatory biomarkers, when compared with those who do not respond in this timeframe (i.e. 
primary non-responders) (Tak, 2012). Secondary non-responders, on the other hand, are thought to fail 
treatment via an entirely different mechanism. These are patients who improve initially as primary 
responders do but after 6 months or more of treatment begin to become unresponsive to it, marked by 
a substantial loss of efficacy. It has been shown that this type of failure is at least partly precipitated by 
the development of anti-drug antibodies (Wolbink, et al., 2006). 
 Given the data in the present study it might be possible to correlate certain patient baseline 
variables with a primary or secondary mechanism of anti-TNF failure based on when that failure 
occurred. None of the baseline variables tested were found to be significant in this analysis. 
Furthermore, a literature review yields no studies with similar analyses for comparison. Instead of using 
clinical characteristics (e.g. age, sex, and diagnosis) as a means to predict treatment success with a first 
course of anti-TNF therapy, most researchers have apparently focused on the outcome of that first trial 
of therapy to guide subsequent treatment decisions. For instance, one author presents an algorithm 
positing that a primary non-responder, whose disease is relatively less TNF-dependent, will likely not 
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respond well to a second anti-TNF agent (Tak, 2012). However, a secondary non-responder, whose loss 
of response may only be due to the development of specific anti-drug antibodies, might respond well to 
a second course of anti-TNF therapy. 
 
4.2.2 Survival of the Second Course of anti-TNF Therapy 
a) First vs. Second Course of Anti-TNF Therapy in patients who tried both 
 The final stage of analysis attempted to determine if a positive response to a second course of 
anti-TNF therapy was indeed possible. A paired samples t-test was used to compare mean drug survival 
of first and second courses of anti-TNF therapy among the segment of the patient population who tried 
both. Overall, survival of the second course of therapy was no different from the first course (19.83 vs 
18.10 months, p = 0.443). In contrast, similar studies in the literature have consistently found that anti-
TNF therapy is more efficacious in biologically naïve patients than in those trying a second course. An 
example is a study which compared biologic survival and periodic ACR scores among RA patients who 
were biologically naïve, first-time switchers, or second-time switchers. The authors observed that the 
OR for an ACR20/50/70 response was consistently <0.6 for first-time switchers vs. biologically naïve 
patients, and that the latter group remained on their ant-TNF therapy significantly longer as well 
(Greenberg, et al., 2012). A study examining anti-TNF agent survival in 1436 AS patients found a similar 
result in that disease, observing that median drug survival for first, second, and third courses were 3.1, 
1.6, and 1.8 years, respectively (Glintborg, et al., 2013). Finally, a study comparing different courses of 
treatment in a large, generalized inflammatory arthritis population found that patients were more than 
twice as likely to persist on a first course of anti-TNF therapy than on a second course (HR 2.17 for anti-
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TNF survival) (Duclos, et al., 2006). This result was still significant when the analysis was done separately 
for interruption due to either inefficacy or intolerance. 
b) All patients analyzed by Disease and by anti-TNF Agent 
 When the second course of anti-TNF therapy was analyzed separately and drug survival of the 3 
diagnoses was compared, both crude Kaplan-Meier analysis and Cox proportional hazards modeling 
showed that the average drug survival for PsA patients was significantly longer than that for RA patients. 
Interestingly, this finding differs from what was found in the corresponding first-course analysis, where 
AS patients survived longest on anti-TNF therapy. However, it is still somewhat in keeping with the 
findings of previous studies comparing first course survival, which show superior anti-TNF survival in SpA 
patients vs. RA patients (Carmona, et al., 2006; Duclos, et al., 2006). Unfortunately, no similar studies 
were found in the literature which compared second-course anti-TNF survival by indication. 
 The comparison of second-course survival among the 3 different anti-TNF types in the entire 
inflammatory arthritis patient population revealed no significant differences between drugs. With the 
exception of the analysis done on RA patients, this is consistent with the findings generated in the first-
course survival analysis. Again, there are no similar studies in the literature comparing second-course 
anti-TNF survival by anti-TNF agent.  However, the findings here are similar to those obtained in 
previous studies comparing first-course anti-TNF survival, where the general consensus is that 
etanercept, adalimumab, and infliximab perform fairly similarly (McLeod, et al., 2007; Mendoza, et al., 
2010; Thorlund, et al., 2012). 
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4.3 Limitations of the Study 
 Many of the limitations of the present study stem from its retrospective, observational design. 
Despite all the previously discussed advantages this type of study has to offer over an RCT with respect 
to observing real-life conditions, its internal validity is reduced due to the heterogeneous nature of its 
patients and its non-standardized intervention administration. Also, drug survival was found to be 
somewhat unreliable as a surrogate outcome for drug efficacy. 
 The most significant limitation with respect to population selection was the inability to generate 
a sample size large enough to power our study; according to our power analysis, only one comparison in 
the primary analysis was adequately powered (anti-TNF survival in AS vs. PsA). It is also evident by 
examining the 95% confidence intervals generated throughout the Results section that statistical power 
was lacking in most analyses (i.e. most confidence intervals were wide and overlapped HR=1 by a 
significant margin). Population selection was limited to whichever patients retrospectively met the study 
criteria at the 2 centers available to the investigators and, unfortunately, this produced a sample size 
which was not adequate to power the study. Such a small sample size not only impaired the power of 
analyses undertaken in the study but also prevented the undertaking of certain analyses which may 
have been insightful. For example, a comparison of drug survival between a first and second course of 
anti-TNF therapy could only be done on a general level, even though it would have been more relevant 
to compare courses for each of the 3 diagnoses.  
Furthermore, while the use of non-restrictive exclusion criteria did help to increase the patient 
population size, this strategy was also problematic in that it created marked heterogeneity in the 
population. Heterogeneity can certainly be beneficial in increasing study validity if it is properly 
accounted for in the analysis with the use of additional variables and stratification. However, given the 
small sample sizes available in the present study such stratification could not be accommodated without 
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a significant loss in power. An example of this unchecked heterogeneity would be disease activity among 
the patients. Because this variable was deliberately not stratified, it is possible that a significant finding 
such as AS patients surviving longer on primary anti-TNF therapy than either PsA or RA patients may in 
fact be due to a much higher proportion of milder disease activity in the AS patients who were included 
in the study. Another example would be patients’ disease antibody status [i.e. rheumatoid factor (RF), 
anti-nuclear antibody (ANA)] as well as their disease duration. 
Another source of heterogeneity in the patient population which may have skewed survival 
outcomes was the use of two very different study settings, NL and Toronto. This issue would have 
affected any analyses involving AS patients, as they were the only group with patients drawn from both 
settings. In this study, a significant effort was made to standardize all of the data by controlling for 
several important covariates in each of the Cox regression models. However, it is certainly possible that 
one or more key differences between the NL and Toronto populations were not accounted for, resulting 
in some degree of confounding bias. For example, there was likely a disparity in average disease severity 
between the two populations, owing to the different methods of referral between the two settings: AS 
patients in the NL setting were referred to their rheumatologist by their family physician, whereas AS 
patients in the Toronto setting were referred to a single rheumatologist (an expert in AS specifically) by 
their previous rheumatologist. Therefore, although not assessed in this study, disease severity was likely 
greater in the Toronto AS population, which may have decreased its anti-TNF survival. 
A lack of control with respect to intervention administration, while consistent with our intended 
observational design, also significantly limited the internal validity of this study. It was not inherently 
problematic that there were dissimilar proportions of patients taking each of the 3 anti-TNF agents 
within each diagnosis; in fact, this dissimilarity likely captures the reality of clinical practice, which was 
our intent. However, the preferential use of certain anti-TNF agents for patients who are predisposed to 
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poorer drug survival may have been an issue. For instance, one factor which may have limited the 
sample size and average drug survival for infliximab is that it tends to be prescribed mostly for patients 
with more severe disease. This is due to that drug’s cumbersome, intravenous administration; 
etanercept and adalimumab are more conveniently administered subcutaneously. An additional 
administrative factor which may have inflated the average drug survival for infliximab is that its dose 
and/or frequency is commonly escalated mid-course in patients who are beginning to lose drug effect; 
this cannot typically be done with etanercept or adalimumab.  
The use of MTX presents a similar problem in this study. Although recommended to be used in 
combination with an anti-TNF agent for the treatment of RA and many forms of PsA (Schur, et al., 2013; 
Gladman, 2010), it is not used as systematically as it could be. This is likely due to the wide variety of 
adverse events associated with its use, its teratogenicity, and some of the lifestyle changes required 
while taking it (e.g. abstaining from alcohol consumption). Thus, the reason why MTX did not have any 
significant effect on drug survival in RA and PsA patients may be that it simply was not used when it was 
indicated. This is likely another accurate reflection of clinical practice, but it detracts from the validity of 
any statement made in this study regarding the efficacy of concomitant MTX therapy. 
A further limitation with respect to interventions was the inability to control the use of other 
medications which may have interacted with the study interventions. For example, apart from 
prednisone and MTX, the use of concomitant medications such as NSAIDs and DMARDs was not 
controlled for in this study. This is problematic since these drugs are capable of improving disease 
severity and thus may have altered the survival of anti-TNF therapy for some patients. Furthermore, 
even though prednisone and MTX use was accounted for here, the starting doses for these drugs, which 
vary considerably, were not. This variability may have the potential to alter anti-TNF survival, 
introducing additional bias. 
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A final limitation associated with intervention administration would be patient access. 
Unfortunately, because anti-TNF therapy is very expensive ($15,000-25,000 annually) (Bonafede, et al., 
2012), there are some patients with inflammatory arthritis who cannot afford it. While the NLPDP does 
provide coverage for most patients who require it, the process of obtaining anti-TNF therapy is still 
much easier and faster for those who are privately insured. Whereas a privately insured patient can 
usually obtain anti-TNF coverage as soon as their rheumatologist deems this therapy is necessary, a 
patient covered by the NLPDP may need to meet several other criteria before they receive their anti-TNF 
agent. For example, according to the NLPDP’s “Criteria for the coverage of special authorization drugs”, 
an RA patient seeking NLPDP coverage for adalimumab must have previously failed an adequate trial of 
at least 3 traditional DMARDs in sequence (or a combination of at least 2 DMARDs) and have failed an 
adequate trial of leflunomide before coverage will be provided (Government of Newfoundland and 
Labrador, 2013). NLPDP requirements for the other inflammatory arthritides and anti-TNF agents are 
similarly stringent. The impact of this problem on the present study is that there is likely a hidden subset 
of patients in the population whose anti-TNF survival is significantly affected by the timeliness of their 
treatment; certain patients may be starting their anti-TNF therapy when it is in fact too late for these 
drugs to have much therapeutic effect, a finding which has been documented previously (Tillett, et al., 
2013). 
The outcomes of this study and how they were reported represent another source of limitation 
here. Despite its accepted reliability as an indicator of therapeutic efficacy in several observational 
studies, drug survival is ultimately a surrogate marker for efficacy and should thus be interpreted with 
some caution. As discussed earlier, drug discontinuation occurs for reasons other than inefficacy. This 
includes adverse events, which were measured in this study, but also includes several others which were 
not, such as financial difficulties, pregnancy, and patient choice. Additionally, in some cases there was 
no reason for drug discontinuation reported in a patient’s file. Thus it cannot be concluded that anti-TNF 
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survival is longer in one cohort than in another solely because of anti-TNF efficacy. Drug survival, 
therefore, would be better defined as a non-specific marker which captures a variety of reasons for drug 
discontinuation; its utility here is in identifying when a conscious decision was made to end a therapy, 
which happens for many reasons other than lack of efficacy in the real world. However, if one were 
interested in assessing drug efficacy specifically, a superior outcome measure would have been an ACR 
score for RA and PsA or an ASAS score for AS. These scores more accurately assess disease severity and 
would thus more reliably determine the efficacy of an intervention such as anti-TNF therapy. 
Unfortunately, a prospective RCT would normally be necessary to avail of these outcome measures as 
physicians do not routinely calculate ACR/ASAS scores to monitor patients’ progress on anti-TNF 
therapy. Furthermore, unlike drug survivals for different diseases, ACR scores and ASAS scores are not 
directly comparable with one another. Thus, the comparisons made in this study would not have been 
possible using these latter outcome measures. 
A final source of limitation here would be the use of a paired samples t-test to compare first vs. 
second course drug survival. As was explained in the Results section, comparing survival means instead 
of survival distributions subjects the analysis to bias arising from temporal differences in drug 
availability. For example, infliximab has been available as a treatment for inflammatory arthritis longer 
than adalimumab, allowing for inflation of the mean survival for patients who took infliximab. Because 
they instead compare survival distributions, Kaplan-Meier analysis and Cox regression are not 
susceptible to this temporal bias and are ideal for analyzing survival data. However, these analyses were 
not usable in the unique case of a paired first vs. second course survival analysis due to the total 
absence of survivors in the first-course cohort. Therefore, although it was not ideal due to its temporal 
bias, we felt a paired samples t-test was the optimal method of performing a first vs. second course 
survival analysis in the present study. 
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Chapter 5 Conclusions 
5.1 Significant outcomes 
 Although several drug survival outcomes were investigated in this study, there were relatively 
few significant findings. One was that patients with AS survive longer on first-course anti-TNF therapy 
than do patients with either PsA or RA (when no adjustments are made for covariates). Another was 
that, among patients with RA, adjusted drug survival is longer for patients taking adalimumab than for 
those taking etanercept. Also, among patients with AS it was found that males are significantly less likely 
than females to discontinue anti-TNF therapy. Finally, among patients taking a second course of anti-
TNF therapy, PsA patients survive longer on their anti-TNF than do RA patients, both crudely and when 
adjusted for relevant covariates. 
5.2 Clinical significance of results 
 Because this study generated few statistically significant findings and the outcome measure 
utilized is only a surrogate measure of efficacy, it may be inappropriate to translate any of the findings 
here directly to clinical practice. Interestingly, some of the findings here do help to validate trends 
observed in existing studies. For instance, the superiority of anti-TNF drug survival in AS vs. PsA and RA 
patients has been observed previously; the same is true of superior drug survival in male vs. female AS 
patients. However, the generation of immediately usable, clinically practical data was never the 
intended purpose of this study. Rather, the idea was to address some of the obvious gaps in the medical 
literature, namely the section containing observational studies of anti-TNF therapy for inflammatory 
arthritis. Past studies have mostly investigated the effect of generalized anti-TNF therapy on one form of 
inflammatory arthritis, or one form of anti-TNF therapy on generalized inflammatory arthritis; no study 
could be found that compares the three major anti-TNF agents in each of AS, PsA, and RA. Therefore, it 
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is the comprehensive nature of this study which makes it novel in the literature. The optimum use of its 
findings would be in generating hypotheses for future studies. For instance, would a real-life, 
longitudinal study using a more direct measure of efficacy such as disease scores produce findings 
similar to those seen in this study? It might also be useful to simply repeat the present real-life drug 
survival study except with appropriately powered sample sizes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
78 
 
References 
Aggarwal R and et al Anti–Citrullinated Peptide Antibody Assays and Their Role in the Diagnosis of 
Rheumatoid Arthritis [Journal] // Arthritis & Rheumatism. - 2009. - 11 : Vol. 61. - pp. 1472-1483. 
Aletaha Daniel and et al. 2010 Rheumatoid arthritis classification criteria: an American College of 
Rheumatology/European League Against Rheumatism collaborative initiative [Journal] // Ann Rheum 
Dis. - 2010. - Vol. 69. - pp. 1580-1588. 
Allied 100 AED Superstore [Online] // AED Superstore. - 2011. - November 20, 2011. - 
http://www.aedsuperstore.com/. 
American Heart Association Part 4: The Automated External Defibrillator: Key Link in the Chain of 
Survival [Journal] // Circulation. - 2000. - Vol. 102. - pp. I60-76. 
American Heart Association Physical Activity Improves Quality of Life [Online] // American Heart 
Association. - January 26, 2011. - November 20, 2011. - 
http://www.heart.org/HEARTORG/GettingHealthy/PhysicalActivity/StartWalking/Physical-activity-
improves-quality-of-life_UCM_307977_Article.jsp#.TsnDEILfh8E. 
Antoni C and et al Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 
trial. [Journal] // Ann Rheum Dis. - 2005. - 8 : Vol. 64. - pp. 1150-1157. 
Antoni C E and et al Sustained benefits of infliximab therapy for dermatologic and articular 
manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis 
controlled trial (IMPACT). [Journal] // Arthritis Rheum. - 2005. - 4 : Vol. 52. - p. 1227. 
Bal A and et al Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity 
parameters in ankylosing spondylitis. [Journal] // Clin Rheumatol. - 2007. - 2 : Vol. 26. - pp. 211-215. 
Balandraud N and et al Epstein-Barr virus load in the peripheral blood of patients with rheumatoid 
arthritis: accurate quantification using real-time polymerase chain reaction. [Journal] // Arthritis 
Rheum.. - 2003. - 5 : Vol. 48. - pp. 1223-1228. 
Barton Anne HLA and other susceptibility genes in rheumatoid arthritis. [Online] // UpToDate. - October 
3, 2010. - March 14, 2011. - http://www.uptodate.com/contents/hla-and-other-susceptibility-genes-in-
rheumatoid-arthritis?source=see_link. 
Bombardier C and Maetzel A Pharmacoeconomic evaluation of new treatments: efficacy versus 
effectiveness studies? [Journal] // Ann Rheum Dis. - 1999. - Suppl I : Vol. 58. - pp. I82-I85. 
Bonafede M MK and et al Cost per Treated Patient for Etanercept, Adalimumab, and Infliximab Across 
Adult Indications: a Claims Analysis [Journal] // Adv Ther. - 2012. - 3 : Vol. 29. - pp. 234-248. 
79 
 
Breban M and et al Familial and genetic aspects of spondyloarthropathy. [Journal] // Rheumatic Dis Clin 
of North America. - 2003. - Vol. 29. - pp. 575-594. 
Brown M and et al Genetics of ankylosing spondylitis. [Journal] // Clin Exp Rheumatol.. - 2002. - 6 Suppl 
28 : Vol. 20. - pp. S43-49. 
Brown Matthew A and et al. Identification of major loci controlling clinical manifestations of ankylosing 
spondylitis [Journal] // Arthritis & Rheumatism. - 2003. - 8 : Vol. 48. - pp. 2234-2239. 
Buskila D and et al Patients with rheumatoid arthritis are more tender than those with psoriatic 
arthritis. [Journal] // J Rheumatol. - 1992. - 7 : Vol. 19. - p. 1115. 
Canadian Medical Association Medical Professionalism [Report]. - 2005. 
Carmona Loreto and et al Survival of TNF antagonists in spondylarthritis is better than in rheumatoid 
arthritis. Data from the Spanish registry BIOBADASER. [Journal] // Arthritis Research & Therapy. - 2006. - 
3 : Vol. 8. - p. R72. 
Cassell Sarah and Kavanaugh Arthur Psoriatic arthritis: Pathogenesis and novel immunomodulatory 
approaches to treatment [Journal] // Journal of Immune Based Therapies and Vaccines. - 2005. - 6 : Vol. 
3. 
Chen Y-F and et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab 
for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-
effectiveness [Journal] // Health Technology Asessment. - 2006. - 42 : Vol. 10. - pp. 1-248. 
Chou C T and et al Cytokine production from peripheral blood mononuclear cells in patients with 
ankylosing spondylitis and their first-degree relatives. [Journal] // Arch Med Res.. - 2007. - 2 : Vol. 38. - 
pp. 190-195. 
Choy E H and Panayi G S Cytokine pathways and joint inflammation in rheumatoid arthritis. [Journal] // 
N Engl J Med. - 2001. - 12 : Vol. 344. - pp. 907-916. 
Davis J C and et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating 
ankylosing spondylitis: a randomized, controlled trial. [Journal] // Arthritis & Rheumatism. - 2003. - 11 : 
Vol. 48. - pp. 3230-3236. 
Duclos Muriel and et al. Retention Rates of Tumor Necrosis Factor Blockers in Daily Practice in 770 
Rheumatic Patients [Journal] // Journal of Rheumatology. - 2006. - 12 : Vol. 33. - pp. 2433-2439. 
Elliott M J and et al Randomised double-blind comparison of chimeric monoclonal antibody to tumour 
necrosis factor α (cA2) versus placebo in rheumatoid arthritis [Journal] // Lancet. - 1994. - 8930 : Vol. 
344. - pp. 1105-1110. 
Eyre S and et al High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis 
[Journal] // Nat Genet. - 2012. - 12 : Vol. 44. - pp. 1336-1340. 
80 
 
Feltkamp T E and et al Spondyloarthropathies in eastern Asia. [Journal] // Curr Opin Rheumatol.. - 
2001. - 4 : Vol. 13. - p. 285. 
Ferrell P B and et al Seroepidemiological study of relationships between Epstein-Barr virus and 
rheumatoid arthritis. [Journal] // J Clin Invest.. - 1981. - 3 : Vol. 67. - pp. 681-687. 
Fiorillo M T and et al CD8(+) T-cell autoreactivity to an HLA-B27-restricted self-epitope correlates with 
ankylosing spondylitis. [Journal] // J Clin Invest.. - 2000. - 1 : Vol. 106. - pp. 47-53. 
Geborek P and et al. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical 
experience using a structured follow up programme in southern Sweden [Journal] // Ann Rheum Dis. - 
2002. - 9 : Vol. 61. - pp. 793-798. 
Ghosh Abhishek Symptoms and treatment of rheumatoid arthritis [Online] // Daily Medico. - April 26, 
2011. - May 15, 2011. - http://dailymedico.com/2011/04/symptoms-and-treatment-of-rheumatoid-
arthritis/. 
Gladman D D Traditional and newer therapeutic options for psoriatic arthritis: an evidence-based review 
[Journal] // Drugs. - 2005. - 9 : Vol. 65. - pp. 1223-1238. 
Gladman Dafna D and et al HLA antigens in psoriatic arthritis. [Journal] // J Rheumatol. - 1986. - 3 : Vol. 
13. - pp. 586-592. 
Gladman Dafna D and et al HLA C-locus alleles in psoriatic arthritis. [Journal] // Human Immunol. - 
1999. - Vol. 60. - pp. 259-261. 
Gladman Dafna D and et al Psoriatic arthritis: epidemiology, clinical features, course, and outcome. 
[Journal] // Ann Rheum Dis. - 2005. - Vol. 64. - pp. ii14-ii17. 
Gladman Dafna D Clinical manifestations and diagnosis of psoriatic arthritis [Online] // UpToDate. - 
December 23, 2009. - September 20, 2010. - 
http://www.uptodate.com/online/content/topic.do?topicKey=spondylo/2133&view=print. 
Gladman Dafna D Treatment of Psoriatic Arthritis [Online] // UpToDate. - May 15, 2010. - September 20, 
2010. - http://www.uptodate.com/online/content/topic.do?topicKey=spondylo/6855&view=print. 
Glintborg B and et al Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis 
patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide 
DANBIO registry [Journal] // Ann Rheum Dis. - 2013. - Vol. 72. - pp. 1149-1155. 
Glintborg B and et al Treatment Response, Drug Survival, and Predictors Thereof in 764 Patients With 
Psoriatic Arthritis Treated With Anti–Tumor Necrosis Factor Therapy [Journal] // Arthritis & 
Rheumatism. - 2011. - 2 : Vol. 63. - pp. 382-390. 
81 
 
Gold Laura S and et al Automated External Defibrillators [Online] // UpToDate. - November 24, 2010. - 
November 20, 2011. - http://www.uptodate.com/contents/automated-external-
defibrillators?source=see_link. 
Government of Newfoundland and Labrador The NLDPDP Criteria for the Coverage of Special 
Authorization Drugs [Online] // NL Department of Health and Community Services. - April 1, 2013. - July 
15, 2013. - http://www.health.gov.nl.ca/health/nlpdp/criteria.pdf. 
Gratacos J and et al Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing 
spondylitis: a close correlation between serum IL-6 and disease activity and severity. [Journal] // Br J 
Rheumatol. - 1994. - 10 : Vol. 33. - pp. 927-931. 
Greenberg JD and et al A comparative effectiveness study of adalimumab, etanercept and infliximab in 
biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. 
[Journal] // Ann Rheum Dis. - 2012. - 7 : Vol. 71. - pp. 1134-1142. 
Haddad A and Chandran V How Can Psoriatic Arthritis Be Diagnosed Early? [Journal] // Current 
Rheumatology Reports. - 2012. - 4 : Vol. 14. - pp. 358-363. 
Hawley DJ and et al Are the results of controlled clinical trials and observational studies of second line 
therapy in rheumatoid arthritis valid and generalizable as measures of rheumatoid arthritis outcome: 
analysis of 122 studies. [Journal] // J Rheumatol. - 1991. - 7 : Vol. 18. - pp. 1008-1014. 
Haynes R and et al Clinical Epidemiology: How to do Clinical Practice Research [Book]. - [s.l.] : LWW, 
2006. 
Healthwise, Inc. Ankylosing Spondylitis [Online] // Health.com. - May 14, 2009. - April 22, 2011. - 
http://www.health.com/health/library/mdp/0,,zm6126,00.html. 
Heiberg M S and et al. The comparative one-year performance of anti-tumor necrosis factor α drugs in 
patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a 
longitudinal, observational, multicenter study [Journal] // Arthritis & Rheumatism. - 2008. - 2 : Vol. 59. - 
pp. 234-240. 
Helliwell P S and Taylor W J Classification and diagnostic criteria for psoriatic arthritis. [Journal] // Ann 
Rheum Dis. - 2005. - Vol. 64. - pp. ii3-ii8. 
Hemminki K and et al. Familial associations of rheumatoid arthritis with autoimmune diseases and 
related conditions. [Journal]. - [s.l.] : Arthritis Rheum, 2009. - 3 : Vol. 60. - pp. 661-668. 
Hetland ML and et al Direct Comparison of Treatment Responses, Remission Rates, and Drug Adherence 
in Patients With Rheumatoid Arthritis Treated With Adalimumab, Etanercept, or Infliximab [Journal] // 
Arthritis & Rheumatism. - 2010. - 1 : Vol. 62. - pp. 22-32. 
82 
 
Hyrich Kimme L and et al Outcomes after switching from one anti–tumor necrosis factor alpha agent to 
a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a 
large UK national cohort study. [Journal] // Arthritis Rheum.. - 2007. - 1 : Vol. 56. - pp. 13-20. 
Hyrich KL and et al Predictors of response to anti-TNF therapy among patients with rheumatoid 
arthritis: results from the British Society for Rheumatology Biologics Register [Journal] // 
Rheumatology. - 2006. - Vol. 45. - pp. 1558-1565. 
Ibrahim G and et al The prevalence of psoriatic arthritis in people with psoriasis. [Journal] // Arthritis 
Rheum. - 2009. - 10 : Vol. 61. - pp. 1373-1378. 
Inman R D and et al Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a 
randomized, double-blind, placebo-controlled, phase III trial. [Journal] // Arthritis Rheum.. - 2008. - 11 : 
Vol. 58. - pp. 3402-3412. 
International Genetics of Ankylosing Spondylitis Consortium Identification of multiple risk variants for 
ankylosing spondylitis through high-density genotyping of immune-related loci [Journal] // Nat Genet. - 
2013. - 7 : Vol. 45. - pp. 730-738. 
Jin Juan and et al Clinical application and evaluation of anti-TNF-alpha agents for the treatment of 
rheumatoid arthritis [Journal] // Acta Pharmacologica Sinica. - 2010. - Vol. 31. - pp. 1133-1140. 
Karlson E W and et al A retrospective cohort study of cigarette smoking and risk of rheumatoid arthritis 
in female health professionals. [Journal] // Arthritis Rheum.. - 1999. - 5 : Vol. 42. - pp. 910-917. 
Kavanaugh A and et al Golimumab, a new human tumor necrosis factor alpha antibody, administered 
every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety 
results of a randomized, placebo-controlled study. [Journal] // Arthritis Rheum.. - 2009. - 4 : Vol. 60. - pp. 
976-986. 
Keystone E and et al The ARMADA trial: a double-blind placebo controlled trial of the fully human anti-
TNF monoclonal antibody, adalimumab (D2E7), in patients with active RA on methotrexate (MTX). 
[Journal] // Arthritis Rheum. - 2001. - Vol. 44. - p. S213. 
Keystone E C and et al Golimumab, a human antibody to tumour necrosis factor α given by monthly 
subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-
FORWARD Study [Journal] // Ann Rheum Dis. - 2009. - Vol. 68. - pp. 789-796. 
Keystone Edward C and et al. Once-Weekly Administration of 50 mg Etanercept in Patients With Active 
Rheumatoid Arthritis: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial 
[Journal] // Arthritis & Rheumatism. - 2004. - 2 : Vol. 50. - pp. 353-363. 
Khan Muhammad Asim Update on spondyloarthropathies [Journal] // Ann Intern Med. - 2002. - Vol. 
136. - pp. 896-907. 
83 
 
Klareskog L and et al A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR 
(shared epitope)-restricted immune reactions to autoantigens modified by citrullination. [Journal] // 
Arthritis Rheum.. - 2006. - 1 : Vol. 54. - pp. 38-46. 
Kyle S and et al Guideline for anti-TNF-α therapy in psoriatic arthritis [Journal] // Rheumatology. - 
November 9, 2004. - 3 : Vol. 44. - pp. 390-397. 
Lexi-Comp Adalimumab: Drug Information [Online] // UpToDate. - 2011c. - June 25, 2011. - 
http://www.uptodate.com/contents/adalimumab-drug-
information?source=search_result&selectedTitle=1~90. 
Lexi-Comp Etanercept: Drug Information [Online] // UpToDate. - 2011b. - June 25, 2011. - 
http://www.uptodate.com/contents/etanercept-drug-
information?source=search_result&selectedTitle=1~150. 
Lexi-Comp Golimumab: Drug Information [Online] // UpToDate. - 2011d. - June 25, 2011. - 
http://www.uptodate.com/contents/golimumab-drug-
information?source=search_result&selectedTitle=1~31. 
Lexi-Comp Infliximab: Drug Information [Online] // UpToDate. - 2011a. - June 25, 2011. - 
http://www.uptodate.com/contents/infliximab-drug-
information?source=search_result&selectedTitle=1~150#F182739. 
Maetzel A and et al Meta-analysis of treatment termination rates among rheumatoid arthritis patients 
receiving disease-modifying anti‐rheumatic drugs [Journal] // Rheumatoloigy. - 1999. - 9 : Vol. 39. - pp. 
975-981. 
Maini R N and et al Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus 
placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III 
trial [Journal] // Lancet. - 1999. - 9194 : Vol. 354. - pp. 1932-1939. 
Markenson J A and et al Persistence with anti-tumor necrosis factor therapies in patients with 
rheumatoid arthritis: observations from the RADIUS registry. [Journal] // J Rheumatol. - 2011. - 7 : Vol. 
38. - pp. 1273-1281. 
McInnes Iain B Cytokine networks in rheumatic diseases: Implications for therapy. [Online] // 
UpToDate. - October 3, 2010. - April 12, 2011. - http://www.uptodate.com/contents/cytokine-networks-
in-rheumatic-diseases-implications-for-therapy?source=see_link&anchor=H14#H14. 
McLeod C and et al Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: 
a systematic review and economic evaluation [Journal] // Health Technology Assessment. - 2007. - 28 : 
Vol. 11. 
Mease P J and et al Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. 
[Journal] // Lancet. - 2000. - 9227 : Vol. 356. - p. 385. 
84 
 
Mease P J and et al. Adalimumab for the treatment of patients with moderately to severely active 
psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. [Journal] // Arthritis & 
Rheumatism. - 2005. - 10 : Vol. 52. - pp. 3279-3289. 
Mease P J and et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease 
progression. [Journal] // Arthritis & Rheumatism. - 2004. - 7 : Vol. 50. - pp. 2264-2272. 
Mendoza A and et al Tumour necrosis factor alpha antagonists in established rheumatoid arthritis: 
effectiveness comparative study [Journal] // Med Clin (Barc). - 2010. - 15 : Vol. 134. - pp. 665-670. 
Moll J M and Wright V Psoriatic Arthritis. [Journal] // Semin Arthritis Rheum. - 1973. - 1 : Vol. 3. - pp. 55-
78. 
Moller P and et al Family studies in Bechterew's syndrome (ankylosing spondylitis). [Journal] // Scand J 
Rheumatol. - 1984. - Vol. 13. - pp. 1–10. 
Moreland Larry W and et al Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor 
Necrosis Factor Receptor (p75)–Fc Fusion Protein [Journal] // N Engl J Med. - 1997. - Vol. 337. - pp. 141-
147. 
Mori K and et al Decrease in serum nucleotide pyrophosphatase activity in ankylosing spondylitis 
[Journal] // Rheum. - 2003. - Vol. 42. - pp. 62-65. 
Njobvu P and McGill P Psoriatic arthritis and human immunodeficiency virus infection in Zambia. 
[Journal] // J Rheumatol. - 2000. - 7 : Vol. 27. - pp. 1699-1702. 
Paget A Stephen An In-Depth Overview of Rheumatoid Arthritis [Online] // Hospital for Special Surgery. - 
February 14, 2003. - May 15, 2011. - http://www.hss.edu/conditions_in-depth-overview-of-rheumatoid-
arthritis.asp. 
Perl Andras Mechanisms of viral pathogenesis in rheumatic disease [Journal] // Ann Rheum Dis. - 1999. - 
8 : Vol. 58. - pp. 454-461. 
Peterson Douglas M Overview of the benefits and risks of exercise [Online] // UpToDate. - October 14, 
2011. - November 20, 2011. - http://www.uptodate.com/contents/overview-of-the-benefits-and-risks-
of-exercise?source=search_result&search=aerobic+exercise&selectedTitle=1~150#H22. 
Punzi L and et al Clinical, laboratory and immunogenetic aspects of post-traumatic psoriatic arthritis: a 
study of 25 patients [Journal] // Clinical and Experimental Rheumatology. - 1998. - 3 : Vol. 16. - pp. 277-
281. 
Quilon Augusto and Brent Lawrence The primary care physician's guide to inflammatory arthritis: 
Diagnosis [Journal] // The Journal of Musculoskeletal Medicine. - 2010. - 6 : Vol. 27. - pp. 223-231. 
Rahman P and Elder J T Genetic epidemiology of psoriasis and psoriatic arthritis. [Journal] // Ann Rheum 
Dis. - 2005. - Vol. 64. - pp. ii37-39. 
85 
 
Raine Nina Tiger Country [Book]. - [s.l.] : Arete Books, 2011. 
Rashid T and Ebringer A Ankylosing spondylitis is linked to Klebsiella—the evidence [Journal] // Clin 
Rheumatol. - 2007. - Vol. 26. - pp. 858-864. 
Ritchlin C T and et al Treatment recommendations for psoriatic arthritis. [Journal] // Ann Rheum Dis. - 
2009. - Vol. 68. - pp. 1387-1394. 
Royal College: CanMEDS [Online] // Royal College of Physicians and Surgeons of Canada. - 2012. - 
October 9, 2012. - http://www.royalcollege.ca/portal/page/portal/rc/canmeds. 
Saad Amr A and et al Persistence with anti-tumour necrosis factor therapies in patients with psoriatic 
arthritis: observational study from the British Society of Rheumatology Biologics Register [Journal] // 
Arthritis Research & Therapy. - 2009. - 2 : Vol. 11. - p. R52. 
Sacks Oliver Witty Ticcy Ray [Journal] // London Review of Books. - March 19, 1981. - pp. 3-5. 
Sahly H and et al Humoral immune response to Klebsiella capsular polysaccharides in HLA-B27-positive 
patients with acute anterior uveitis and ankylosing spondylitis [Journal] // Autoimmunity. - 1998. - Vol. 
28. - pp. 209-215. 
Schur P and et al General principles of management of rheumatoid arthritis in adults [Online] // 
UpToDate. - April 22, 2014. - April 23, 2014. - http://www.uptodate.com/contents/general-principles-of-
management-of-rheumatoid-arthritis-in-
adults?source=search_result&search=rheumatoid+arthritis&selectedTitle=3~150#H111271321. 
Schur Peter and et al Overview of the systemic and nonarticular manifestations of rheumatoid arthritis 
[Online] // UpToDate. - March 20, 2014. - April 20, 2014. - 
http://www.uptodate.com/contents/overview-of-the-systemic-and-nonarticular-manifestations-of-
rheumatoid-arthritis?source=search_result&search=rheumatoid+arthritis&selectedTitle=4~150#H38. 
Schur Peter H and Cohen Stanley Treatment of rheumatoid arthritis resistant to initial DMARD therapy 
in adults [Online] // UpToDate. - June 8, 2013. - July 14, 2013. - 
http://www.uptodate.com/contents/treatment-of-rheumatoid-arthritis-resistant-to-initial-dmard-
therapy-in-
adults?detectedLanguage=en&source=search_result&search=rheumatoid+arthritis&selectedTitle=5~15
0&provider=noProvider#H12087392. 
Schur Peter H and et al Nonpharmacologic and preventive therapies of rheumatoid arthritis. [Online] // 
UpToDate. - December 6, 2010. - April 18, 2011. - 
http://www.uptodate.com/contents/nonpharmacologic-and-preventive-therapies-of-rheumatoid-
arthritis?source=see_link. 
86 
 
Schur Peter H and et al Treatment of persistently active rheumatoid arthritis in adults. [Online] // 
UpToDate. - June 10, 2010. - April 12, 2011. - http://www.uptodate.com/contents/treatment-of-
persistently-active-rheumatoid-arthritis-in-adults?source=see_link#H8. 
Schur Peter H and Maini R N Treatment of early, moderately active rheumatoid arthritis [Online] // 
UpToDate. - October 9, 2009. - September 20, 2010. - 
http://www.uptodate.com/online/content/topic.do?topicKey=rheumart/15723&view=print. 
Schur Peter H Pathogenesis of rheumatoid arthritis [Online] // UpToDate. - October 5, 2010. - March 16, 
2011. - http://www.uptodate.com/contents/pathogenesis-of-rheumatoid-
arthritis?source=search_result&selectedTitle=11~150#H11. 
Shamji Mohammed F and et al The pathogenesis of ankylosing spondylitis [Journal] // Neurosurg 
Focus. - 2008. - 1 : Vol. 24. - pp. 1-10. 
Sieper J and et al The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide 
to assess spondyloarthritis. [Journal] // Ann Rheum Dis. - 2009. - Suppl II : Vol. 68. - pp. ii1-ii44. 
Smolen Josef S and et al EULAR recommendations for the management of rheumatoid arthritis with 
synthetic and biological disease-modifying antirheumatic drugs. [Journal] // Ann Rheum Dis. - 2010. - 6 : 
Vol. 69. - pp. 964-975. 
Sokka Tuulikki and Pincus Theodore Most patients receiving routine care for rheumatoid arthritis in 
2001 did not meet inclusion criteria for most recent clinical trials or american college of rheumatology 
criteria for remission. [Journal] // J Rheumatol. - 2003. - 6 : Vol. 30. - pp. 1138-1146. 
Taglione E V and et al Hepatitis C virus infection: prevalence in psoriasis and psoriatic arthritis 
[Journal] // J Rheumatol. - 1999. - 2 : Vol. 26. - pp. 370-372. 
Tak P P A personalized medicine approach to biologic treatment of rheumatoid arthritis: a preliminary 
treatment algorithm [Journal] // Rheumatology. - 2012. - Vol. 51. - pp. 600-609. 
Tani Y and et al Antibodies to Klebsiella, Proteus, and HLA-B27 peptides in Japanese patients with 
ankylosing spondylitis and rheumatoid arthritis. [Journal] // J Rheumatol.. - 1997. - 1 : Vol. 24. - pp. 109-
114. 
Taurog J D and et al The Germfree State Prevents Development of Gut and Joint Inflammatory Disease 
in HLA-B27 Transgenic Rats [Journal] // J Exp Med. - 1994. - Vol. 180. - pp. 2359-2364. 
Taylor W and et al Classification Criteria for Psoriatic Arthritis [Journal] // Arthritis & Rheumatism. - 
2006. - 8 : Vol. 54. - pp. 2665-2673. 
The Association of Faculties of Medicine of Canada Chapter 2: Determinants of Health and Health 
Inequities [Online] // AFMC Primer on Population Health. - 2009. - November 20, 2011. - 
http://phprimer.afmc.ca/Part1-
87 
 
TheoryThinkingAboutHealth/Chapter2DeterminantsOfHealthAndHealthInequities/DeterminantsofHealt
h. 
The Royal College of Physicians and Surgeons of Canada CanMEDS 2005 Framework [Report]. - 2005. 
The Royal College of Physicians and Surgeons of Canada CanMEDS 2005 Framework [Report]. - 2005. 
The Royal College of Physicians and Surgeons of Canada CanMEDS Framework [Report]. - 2005. 
Thorlund K and et al Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an 
indirect comparison meta-analysis [Journal] // Biologics: Targets and Therapy. - 2012. - Vol. 6. - pp. 417-
427. 
Tillett W and et al Smoking and delay to diagnosis are associated with poorer functional outcome in 
psoriatic arthritis. [Journal] // Ann Rheum Dis.. - August 2013. - 8 : Vol. 72. - pp. 1358-1361. 
Uhlig T and Kvien T K Is rheumatoid arthritis disappearing? [Journal] // Ann Rheum Dis. - 2005. - Vol. 
64. - pp. 7-10. 
van de Putte L B and et al Efficacy of the fully human anti-TNF antibody D2E7 in rheumatoid arthritis. 
[Journal] // Arthritis Rheum. - 1999. - Vol. 42. - p. S400. 
van de Putte L B and et al. Efficacy and safety of adalimumab as monotherapy in patients with 
rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. 
[Journal] // Ann Rheum Dis.. - 2004. - 5 : Vol. 63. - pp. 508-516. 
van der Heijde D and et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: 
results of a multicenter, randomized, double-blind, placebo-controlled trial. [Journal] // Arthritis & 
Rheumatism. - 2006. - 7 : Vol. 54. - pp. 2136-2146. 
van der Heijde D and et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: 
results of a randomized, placebo-controlled trial (ASSERT). [Journal] // Arthritis & Rheumatism. - 2005. - 
2 : Vol. 52. - pp. 582-591. 
Veale Douglas and FitzGerald Oliver Psoriatic Arthritis [Journal] // Best Practice & Research Clinical 
Rheumatolgy. - 2002. - 4 : Vol. 16. - pp. 523-535. 
Venables P JW and Maini R N Clinical features of rheumatoid arthritis [Online] // UpToDate. - February 
9, 2010. - September 9, 2010. - 
http://www.uptodate.com/online/content/topic.do?topicKey=rheumart/3022&view=print. 
Wegner N and et al Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of 
rheumatoid arthritis. [Journal] // Immunol Rev.. - 2010. - 1 : Vol. 233. - pp. 34-54. 
Wendling D and Prati C Spondyloarthritis and smoking: towards a new insight into the disease. 
[Journal] // Expert Rev Clin Immunol.. - June 2013. - 6 : Vol. 9. - pp. 511-516. 
88 
 
Wolbink G J and et al Development of antiinfliximab antibodies and relationship to clinical response in 
patients with rheumatoid arthritis. [Journal] // Arthritis Rheum. - 2006. - Vol. 54. - pp. 711-715. 
Yu David and et al General guidelines for use of anti-tumor necrosis factor alpha agents in ankylosing 
spondylitis and in peripheral and non-radiographic axial spondyloarthritis [Online] // UpToDate. - 
October 7, 2013. - April 20, 2014. - www.uptodate.com/contents/general-guidelines-for-use-of-anti-
tumor-necrosis-factor-alpha-agents-in-ankylosing-spondylitis-and-in-peripheral-and-non-radiographic-
axial-spondyloarthritis. 
Yu David T Clinical manifestations of ankylosing spondylitis in adults [Online] // UpToDate. - June 16, 
2010. - September 20, 2010. - 
http://www.uptodate.com/online/content/topic.do?topicKey=spondylo/2604&view=print. 
Yu David T Guidelines for cost-conscious use of anti-tumor necrosis factor alpha agents in ankylosing 
spondylitis in the United States. [Online] // UpToDate. - February 15, 2011. - April 12, 2011. - 
http://www.uptodate.com/contents/guidelines-for-cost-conscious-use-of-anti-tumor-necrosis-factor-
alpha-agents-in-ankylosing-spondylitis-in-the-united-states?source=see_link. 
Yu David T Pathogenesis of spondyloarthritis. [Online] // UpToDate. - February 15, 2011. - March 16, 
2011. - http://www.uptodate.com/contents/pathogenesis-of-
spondyloarthritis?source=search_result&selectedTitle=7~150. 
Yu David T Treatment and prognosis of ankylosing spondylitis in adults [Online] // UpToDate. - June 16, 
2010a. - September 20, 2010. - 
http://www.uptodate.com/online/content/topic.do?topicKey=spondylo/5520&view=print. 
Zochling J and et al ASAS/EULAR recommendations for the management of ankylosing spondylitis. 
[Journal] // Ann Rheum Dis. - 2006. - Vol. 65. - pp. 442-452. 
 
 
 
 
 
 
 
89 
 
Appendices 
Appendix A: Data collection form (St. John’s center patients only) for TNF-α antagonist survival analysis 
Demographics: 
Study ID: Subject Initials: DoB (yyyy): Sex:  M / F 
Rheumatic Diagnosis: □ RA        □ AS        □ PsA        □ Other  ____________________________________ 
Date of Onset (yyyy):  Date of Diagnosis (yyyy): 
Smoker □ No                 □ Yes       # of Yrs ___________      # of Cigarettes __________ 
Height:    _________________  □ Cm     □ In Weight:    ______________  □ Kg      □ Lb   
 
 
 
Previous Medications: 
NSAIDs: N / Y   Type/Dose: ___________________________________________ 
Prednisone: N / Y   Dose: ________________________________________________ 
MTX: N / Y   Dose: ________________________________________________ 
Plaquenil: N / Y   Dose: ________________________________________________ 
Arava: N / Y   Dose: ________________________________________________ 
Other DMARDs: N / Y   Type/Dose: ___________________________________________ 
 
 
 
 
1st anti-TNF: 
Anti-TNF □ Etanercept        □ Adalimumab        □ Infliximab        □ Golimumab      □ Abatacept    □ Rituximab    
Start (dd/mm/yyyy): Stop (dd/mm/yyyy): 
Reason for stop:   □ Efficacy     □ Adverse event(s)     □ Other  
                              _________________________________________________________________________ 
Medications:              At Start of 1st anti-TNF                                            At most recent visit on 1st anti-TNF 
NSAIDs:  N / Y   Type/Dose: ______________________ N / Y   Type/Dose: ______________________ 
Prednisone:  N / Y   Dose: ___________________________ N / Y   Dose: ___________________________ 
MTX:  N / Y   Dose: ___________________________ N / Y   Dose: ___________________________ 
Plaquenil: N / Y   Dose: ___________________________ N / Y   Dose: ___________________________ 
Arava: N / Y   Dose: ___________________________ N / Y   Dose: ___________________________ 
Other 
DMARDs: N / Y   Type/Dose: _______________________ N / Y   Type/Dose: ______________________ 
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2nd anti-TNF: 
Anti-TNF □ Etanercept        □ Adalimumab        □ Infliximab        □ Golimumab      □ Abatacept    □ Rituximab    
Start (dd/mm/yyyy): Stop (dd/mm/yyyy): 
Reason for stop:   □ Efficacy     □ Adverse event(s)     □ Other  
                              _________________________________________________________________________ 
Medications:              At Start of 2nd anti-TNF                                            At most recent visit on 2nd anti-TNF 
NSAIDs:  N / Y   Type/Dose: ______________________ N / Y   Type/Dose: ______________________ 
Prednisone:  N / Y   Dose: ___________________________ N / Y   Dose: ___________________________ 
MTX:  N / Y   Dose: ___________________________ N / Y   Dose: ___________________________ 
Plaquenil: N / Y   Dose: ___________________________ N / Y   Dose: ___________________________ 
Arava: N / Y   Dose: ___________________________ N / Y   Dose: ___________________________ 
Other 
DMARDs: N / Y   Type/Dose: ______________________ N / Y   Type/Dose: ______________________ 
 
 
3rd anti-TNF: 
Anti-TNF □ Etanercept        □ Adalimumab        □ Infliximab        □ Golimumab      □ Abatacept    □ Rituximab    
Start (dd/mm/yyyy): Stop (dd/mm/yyyy): 
Reason for stop:   □ Efficacy     □ Adverse event(s)     □ Other  
                              _________________________________________________________________________ 
Medications:              At Start of 3rd anti-TNF                                             At most recent visit on 3rd anti-TNF 
NSAIDs:  N / Y   Type/Dose: ______________________ N / Y   Type/Dose: ______________________ 
Prednisone:  N / Y   Dose: ___________________________ N / Y   Dose: ___________________________ 
MTX:  N / Y   Dose: ___________________________ N / Y   Dose: ___________________________ 
Plaquenil: N / Y   Dose: ___________________________ N / Y   Dose: ___________________________ 
Arava: N / Y   Dose: ___________________________ N / Y   Dose: ___________________________ 
Other 
DMARDs: N / Y   Type/Dose: ______________________ N / Y   Type/Dose: ______________________ 
 
 
Disease Status  
AS: 
1st anti-TNF BASDAI at start: _________ BASDAI at 6 mo: _________ 
2nd anti-TNF BASDAI at start: _________ BASDAI at 6 mo: _________ 
3rd anti-TNF BASDAI at start: _________ BASDAI at 6 mo: _________ 
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RA/PsA: 
1st anti-TNF ACR at 6 mo:   □ ACR<20       □ ACR20        □ ACR50     □ ACR70   
2nd anti-TNF ACR at 6 mo:   □ ACR<20       □ ACR20        □ ACR50     □ ACR70   
3rd anti-TNF ACR at 6 mo:   □ ACR<20       □ ACR20        □ ACR50     □ ACR70   
 
 
